

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020735
Article Type:	Research
Date Submitted by the Author:	23-Nov-2017
Complete List of Authors:	Gou, Xiaoyun; West China Second University Hospital, Sichuan University, Chengdu 610041, China Yang, Lei; West China Second University Hospital, Sichuan University, Chengdu 610041, China Pan, Lingli; West China Second University Hospital, Sichuan University, Chengdu 610041, China Xiao, Dongqiong; West China Second University Hospital, Sichuan University, Chengdu 610041, China
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Neurology
Keywords:	bronchopulmonary dysplasia, cerebral palsy, neurodevelopment, infant

SCHOLARONE™  
Manuscripts

View Only

1  
2  
3 **The association between bronchopulmonary dysplasia and cerebral palsy in**  
4 **children: A meta-analysis**  
5

6  
7 Xiaoyun Gou<sup>1,2#</sup>, Lei Yang<sup>1,2#</sup>, Lingli Pan<sup>1,2</sup>, Dongqiong Xiao<sup>1,2\*</sup>  
8

9  
10 <sup>1</sup>Department of Pediatrics, West China Second University Hospital, Sichuan University,  
11 Chengdu 610041, China  
12

13  
14 <sup>2</sup>Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan  
15 University), Ministry of Education, Chengdu 610041, China  
16

17  
18 # These authors contributed equally to the study.  
19

20  
21 **\*Corresponding author**  
22

23 **Dongqiong Xiao, MD**  
24

25 Department of Pediatrics,  
26

27 West China Second University Hospital,  
28

29 Sichuan University, Chengdu, Sichuan 610041, China  
30

31 Email: m13881749494@163.com  
32

33 Telephone: +86-28-85502273  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To investigate whether bronchopulmonary dysplasia (BPD) affects the neurodevelopment outcomes especially cerebral palsy (CP) and to identify the factors that may explain these differences.

**Data sources:** We used EMBASE, PubMed and Web of Science to conduct a meta-analysis of studies published before September 1, 2017 with English, with titles or abstracts that discussed an association between BPD and CP.

**Study selection:** Case-control studies and cohort studies were included.

**Data extraction and synthesis:** All review stages were conducted by 2 reviewers independently. Data synthesis was undertaken via meta-analysis of available evidence.

**Main outcomes and measures:** Neurodevelopment outcomes, especially cerebral palsy after exposure to BPD.

**Results:** Among 1234 initially identified studies, we selected those that addressed an association between BPD and CP according to our preselected inclusion criteria. Our meta-analysis included 11 studies. According to a random effect model, BPD was significantly associated with both cerebral palsy (ORs=2.10: 95% CI 1.57 to 2.82) in preterm infants. Factors explaining differences in the study results included study design, the definition of BPD, the time of diagnosis of CP, and whether the studies adjusted for potential confounders.

**Conclusion** This study suggests that BPD is a risk factor for cerebral palsy. Further studies are required to confirm these results and to detect the influence of variables across studies.

**Keywords:** bronchopulmonary dysplasia; cerebral palsy; neurodevelopment; infant

### Strengths and limitations of the study

\*Infants exposed to bronchopulmonary dysplasia (BPD) were more likely to develop cerebral palsy (CP).

\*We conducted a meta-analysis to evaluate the potential association between BPD and CP in preterm infants. Factors explaining differences in the study results included study design, the definition of BPD, the time of diagnosis of CP, and whether the studies adjusted for potential confounders.

\*We failed to identify the source of heterogeneity.

\*The association between BPD and CP is recognized but whether this is because the same infants are susceptible to both adverse outcomes or whether BPD truly influence the development of CP cannot be determined from the existing literature. Further studies are required to confirm these results and to detect the influence of variables across studies.

\*The number of studies included is limited, and therefore, the results of this meta-analysis should be interpreted with caution.

## Introduction

Despite advances in obstetric and neonatal care, the prevalence of cerebral palsy (CP) has been increased<sup>1</sup>, and the etiology of CP remains poorly understood. Evidence shows that prenatal factors, including maternal age<sup>2</sup>, education<sup>3,4</sup>, obesity<sup>5-7</sup>, race<sup>8</sup>, chorioamnionitis<sup>9</sup> and hypertension<sup>10</sup> contribute to CP. Yet, the neonatal factors play a relatively minor role.

Bronchopulmonary dysplasia (BPD) has been implicated as a potential neonatal factor of CP<sup>11</sup>. BPD is common in preterm and low birthweight infants born at 24 to 26 weeks of gestation<sup>12</sup>. The lung is in the canalicular stage from 16 to 28 weeks, and it is in the saccular stage from 28 to 36 weeks. Alveoli are not uniformly present until 36 weeks. Thus, premature birth and the initiation of pulmonary gas exchange arrest normal alveolar and distal vascular development, and subsequent BPD<sup>12</sup>. Maternal infection, especially maternal chorioamnionitis was associated with an increased risk of BPD<sup>13</sup>. The inconsistencies in the definition of BPD contribute to variation in incidence of BPD. Some studies defined as oxygen dependency at 36 weeks post-menstrual age (PMA), yet, others defined as 28 or more days duration of oxygen dependency during hospitalization<sup>13</sup>. Cerebral palsy, cognitive delay, and hearing loss are important and commonly reported adverse outcomes in very premature infants<sup>14</sup>. It is postulated that BPD can lead to neonatal brain injury and subsequent CP.

A number of studies have assessed the relationship between BPD and CP in premature infants, but most have not examined a significant association, for example, one study defined BPD as 28 days duration of oxygen dependency<sup>15</sup>, and one study<sup>16</sup> evaluated the association between BPD (oxygen dependency at 36 weeks) and quadriparas and diparesis. Yet, any other studies<sup>17,18</sup> showed a significant association between BPD and CP. We conducted a meta-analysis to evaluate the potential association between BPD and CP in preterm infants.

## Methods

**Retrieval of studies.** The PubMed, EMBASE, and Web of Science databases were searched through September 1, 2017. The search of bronchopulmonary dysplasia was performed using the following keywords and subject terms: “bronchopulmonary dysplasia”, or “BPD\*”, or “lung dysplasia”, or “Dysplasia, Bronchopulmonary”, or “Bronchopulmonary Dysplasia”, using “OR” to link relevant text within the search field. To acquire studies related to cerebral palsy, “OR” was used to associate the key words, which included “cerebral palsy”, “Crebral pals\*”, “spastic\*”, “quadripleg\*” and “CP”. We combined these terms using “AND” to retrieve the studies. We restricted the search to human studies published in English.

### **Inclusion/exclusion criteria.**

The study inclusion criteria were as follows: (1) the study evaluated the association between bronchopulmonary dysplasia (BPD) and the risk of CP in children; (2) the study was published in English; (3) case-control or cohort study design; (4) the study described the assessment of exposure and outcome; and the study reported unadjusted and/or adjusted relative ratios (RRs) and corresponding 95% confidence intervals (CIs), unadjusted and/or adjusted odds ratios (ORs) estimates and 95% CIs.

The exclusion criteria were as follows: (1) a review or meta-analysis or a case report; (2) the study was not published in English; (3) the article described an animal experiment study; (4) a study with overlapping data; (5) the study was not reported the children’s CP or disability affected by BPD, and did not have useable data.

### **Study selection**

The retrieved studies were screened by reading the titles and abstracts, and two authors (Xiaoyun Gou and Lei Yang) subsequently read the full text of the remaining publications independently and then discussed disagreements to reach a consensus.

1  
2  
3 **Data extraction.** The data were independently extracted from the studies by two  
4 reviewers (Xiaoyun Gou and Lei Yang) and included the name of the first author,  
5 publication year, the country of the participants, study design, sample size, gestational  
6 age and/or birthweight, following years, BPD definition, primary outcome, and  
7 adjusted confounders.  
8  
9  
10  
11

12  
13 **Quality evaluation.** The two reviewers (Xiaoyun Gou and Lei Yang) independently  
14 used the Newcastle-Ottawa Scale (NOS)<sup>19</sup> to examine all included studies for their  
15 methodological quality. The reviewers evaluated the quality score via examine the  
16 selection of the study population, comparability and evaluation of exposure and  
17 outcome, with a maximum score of nine. The reviewers resolved disagreements in the  
18 manner previously described.  
19  
20  
21  
22  
23

24 **Statistical analysis.** The original studies included used ORs and/or RRs and 95% CIs  
25 to assess the association between BPD and the risk of CP in children. The ORs and  
26 RRs were directly considered as ORs. We pooled ORs and/or RRs of each study  
27 separately using the Der Simonian-Laird formula (random-effects model)<sup>20</sup>.  
28 Statistical heterogeneity<sup>21</sup> between the studies was assessed using the Q and I<sup>2</sup>  
29 statistics. Values of I<sup>2</sup>>50% and P<0.1 indicated high heterogeneity<sup>9</sup>. We conducted a  
30 stratified analysis based on study design (case-control, cohort), BPD type (oxygen  
31 dependency at 36 weeks' post-menstrual age (PMA), 28 days duration of oxygen  
32 dependency during hospitalization, severe BPD including mechanical ventilation at 36  
33 weeks, not defined BPD), diagnostic criteria for CP (Age <2 years, other),  
34 confounding variables (gestational age, unadjusted estimated). We performed  
35 sensitivity analyses by omitting one study at a time.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 We used Egger's<sup>22</sup> and Begg's<sup>23</sup> tests to assess the publication bias, which was  
48 considered to be statistically significant when p<0.05. We used Stata software,  
49 version 12.0 (StataCorp, College Station, TX) to perform the statistical tests.  
50  
51  
52  
53  
54



## Results

**Literature search.** We identified 1234 potential studies: 195 from PubMed, 523 from EMBASE, 515 from Web of Science and 1 additional study from the related reference. After careful screening, 11 studies that reported the association between BPD and the risk of CP in children were selected for inclusion in this study (see Figure 1). These 11 included studies are summarized in Table 1.

**Characteristics and quality of the included studies.** The included studies were published between 1999 and 2017. Eleven studies evaluated the association between BPD and cerebral palsy in preterm infants. Two<sup>15, 17</sup> of these studies reported no significant association. Eight of the included studies were cohort studies and three<sup>15, 24, 25</sup> of the studies were case-control studies of a high quality (NOS>5). Some of the studies defined the diagnosis of CP more than 2 years, while others defined CP less than 2 years.

### **Bronchopulmonary dysplasia (BPD) and cerebral palsy (CP).**

When the study results were analyzed using random effects model, BPD was significantly associated with both CP (ORs, 2.10; 95%CI, 1.57, 2.82). These infants were preterm infants.

Six studies<sup>16, 17, 24, 26-28</sup> evaluated the association between BPD (oxygen dependence at 36 weeks) and CP in premature infants, with only 1 reporting<sup>17</sup> a no significant association (Figure 2). One study<sup>15</sup> evaluated the association between BPD (oxygen dependence at 28 days) and CP in premature infants with no significant association (OR 1.12, 95%CI, 0.84, 1.49). Three studies<sup>18, 25, 29</sup> evaluated the association (OR 2.80, 95%CI, 2.08, 3.79) without mentioned BPD definition, and 2 studies<sup>16, 30</sup> show severe BPD or mechanical ventilation at 36 weeks (OR 3.44, 95%CI, 1.56, 7.60).

### **Stratified analysis**

1  
2  
3 A stratified analysis was conducted to investigate the possible sources of  
4 heterogeneity in articles of BPD in preterm infants (Table 2). The case-control studies  
5 did not produce significant summary ORs (2.13; 95%CI, 0.85, 5.34), yet, a significant  
6 association was seen in cohort studies ORs (2.15; 95%CI, 1.57,2.94).  
7  
8  
9

10  
11 The definition of CP differed greatly among studies of preterm infants (Table 2).  
12 Of the four studies<sup>16-18,26</sup> that provided adequate information, four studies provided a  
13 minimum age of 2 years for diagnosing CP; Some studies confirm the diagnosis by  
14 performing examination, while others did not. Some studies excluded children with  
15 congenital anomalies<sup>15,17,18</sup>, while others<sup>16,26</sup> did not specify any exclusion criteria.  
16  
17  
18  
19

20  
21 Five studies of BPD(PMA) in premature infants reported ORs controlled for  
22 gestational age. The summary ORs calculated from adjusted gestational age was not  
23 significant smaller than that derived from unadjusted estimates (ORs, 2.29; 95%CI,  
24 1.5, 3.49; vs ORs, 2.01; 1.43, 2.83; Table 2).  
25  
26  
27

### 28 29 **Sensitivity analysis**

30  
31 The resulting summary ORs differed minimally after omitting each of one of the  
32 included studies at a time.  
33  
34

35  
36 **Publication bias.** Asymmetry and publication bias were evaluated by Egger's and  
37 Begg's tests. The pooled results did not support the presence of significant publication  
38 bias (all  $p>0.05$ ).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## Discussion

To our knowledge, this article is the first meta-analysis of the relationship between BPD and risk of CP in children. The results of this meta-analysis, which included 11 studies, showed evidence that BPD appears to be associated with CP in preterm infants.

BPD might affect the neurodevelopment outcome of infants through multiple pathways. A growing body evidence supports that BPD contributes to neonatal brain injury<sup>31</sup>. Experimental BPD with hypoxia leads to central nervous system damage, and subsequent CP<sup>32, 33</sup>. Indeed, the preterm infants with BPD accompany with hypoxia often had oligodendrocytes maturation arrest or injury<sup>34-36</sup>, disruption of myelination and demyelination, and then cause white matter injury<sup>36</sup> and impaired neurodevelopmental outcomes<sup>33</sup>.

To better understand the relationship between BPD and CP, it is crucial to develop consensus definitions of BPD. Most published reports do not apply specific diagnostic criteria for BPD, as a group, these studies produced heterogeneous results. The results of the stratified analysis suggest that a stronger association is seen when used severe or mechanical ventilation at 36 weeks diagnostic criteria in the studies. The studies do not include strict criteria may lead to an over-diagnosis of BPD, which may contribute to the evidence of heterogeneity.

The definition of CP varied between studies; although CP can be difficult to diagnosis in children younger than 2 years, 1 study made the diagnosis in infants younger than 12 months. A consensus definition of CP is required.

Some studies report significant associations between BPD and CP after adjust for potential confounders. Although gestational age appears to be a possible confounder, it may also lie directly in the causal pathway between BPD and CP. BPD is associated with premature delivery, and low gestational age, which is associated with a host of

1  
2  
3 intrinsic vulnerabilities within the brain, that have been implicated in the pathogenesis  
4 of CP. Therefore, if low gestational age resulting in BPD plays a direct role in the  
5 pathogenesis of CP, then adjusting for gestational age will falsely diminish the  
6 observed association between BPD and CP. One study of BPD in premature infants  
7 reported insignificant association when controlling for the confounder variables  
8 including gestational age. It is unclear if this is because BPD does not contribute  
9 independently to CP, or perhaps because gestational age lies on the causal pathway.  
10  
11  
12  
13  
14  
15

16  
17 Other factors may interact with BPD in the pathogenetic pathway leading to CP.  
18 For example, child sex, IVH, Apgar score at 5 minutes, small for gestational age  
19 (SGA), which may contribute to CP lies on the causal pathway. Although the studies  
20 controlled for some confounder variables, many other factors that contribute to CP  
21 may not be excluded.  
22  
23  
24  
25

26  
27 Our meta-analysis is subject to limitations as follows. Firstly, we only included  
28 articles published in English. Secondly, there may be publication bias, incomplete  
29 ascertainment of published studies, and errors in data abstraction. Thirdly, the number  
30 of studies included is small, and therefore, the results of this meta-analysis should be  
31 interpreted with caution. Furthermore, the bias inherent to observational studies are  
32 not eliminated in a quantitative synthesis.  
33  
34  
35  
36  
37

38  
39 Our meta-analysis has some merits. First, the study evaluated the association  
40 between BPD and CP. Second, the study used stratified analysis to explore the  
41 heterogeneity source, yet, we failed to identify the source of heterogeneity.  
42  
43

44  
45 In conclusion, our pooled analyses provide evidence that BPD is significantly  
46 associated with cerebral palsy in children. Future studies that consider additional  
47 factors are required to resolve this issue.  
48  
49  
50  
51  
52  
53  
54

### **Author contributions**

XG and LY contributed to the conception and design of the study, as well as to the drafting of this article. LP contributed to the collection and analysis of the data. DX contributed to the conception and design of the study and approved the final version of the manuscript for submission for publication.

### **Funding**

No financial support for this work.

### **Competing financial interests**

The authors declare that they have no competing financial interests.

### **Data sharing statement**

No additional data are available.

## References

1. Berger A, Witt A, Haiden N, et al. Intrauterine infection with Ureaplasma species is associated with adverse neuromotor outcome at 1 and 2 years adjusted age in preterm infants. *J Perinat Med.* 2009;37(1):72-78.
2. Pan C, Deroche CB, Mann JR, McDermott S, Hardin JW. Is prepregnancy obesity associated with risk of cerebral palsy and epilepsy in children? *J Child Neurol.* Dec 2014;29(12):Np196-201.
3. Villamor E, Tedroff K, Peterson M, et al. Association Between Maternal Body Mass Index in Early Pregnancy and Incidence of Cerebral Palsy. *Jama.* Mar 07 2017;317(9):925-936.
4. Persson M, Johansson S, Villamor E, Cnattingius S. Maternal overweight and obesity and risks of severe birth-asphyxia-related complications in term infants: a population-based cohort study in Sweden. *PLoS Med.* May 2014;11(5):e1001648.
5. Wang Y, Tang S, Xu S, Weng S, Liu Z. Maternal Body Mass Index and Risk of Autism Spectrum Disorders in Offspring: A Meta-analysis. *Sci Rep.* Sep 30 2016;6:34248.
6. Crisham Janik MD, Newman TB, Cheng YW, Xing G, Gilbert WM, Wu YW. Maternal diagnosis of obesity and risk of cerebral palsy in the child. *J Pediatr.* Nov 2013;163(5):1307-1312.

- 1  
2  
3  
4 **7.** Forthun I, Wilcox AJ, Strandberg-Larsen K, et al. Maternal Prepregnancy BMI and  
5  
6 Risk of Cerebral Palsy in Offspring. *Pediatrics*. Oct 2016;138(4).  
7
- 8  
9 **8.** Bear JJ, Wu YW. Maternal Infections During Pregnancy and Cerebral Palsy in the  
10  
11 Child. *Pediatr Neurol*. Apr 2016;57:74-79.  
12
- 13  
14 **9.** Wu YW, Colford JM, Jr. Chorioamnionitis as a risk factor for cerebral palsy: A  
15  
16 meta-analysis. *Jama*. Sep 20 2000;284(11):1417-1424.  
17
- 18  
19 **10.** Kronenberg ME, Raz S, Sander CJ. Neurodevelopmental outcome in children  
20  
21 born to mothers with hypertension in pregnancy: the significance of suboptimal  
22  
23 intrauterine growth. *Developmental Medicine and Child Neurology*. Mar  
24  
25 2006;48(3):200-206.  
26  
27
- 28  
29 **11.** Bregman J, Farrell EE. NEURODEVELOPMENTAL OUTCOME IN INFANTS  
30  
31 WITH BRONCHOPULMONARY DYSPLASIA. *Clinics in Perinatology*. Sep  
32  
33 1992;19(3):673-694.  
34  
35
- 36  
37 **12.** Coalson JJ. Pathology of new bronchopulmonary dysplasia. *Seminars in*  
38  
39 *neonatology : SN*. 2003-Feb 2003;8(1):73-81.  
40
- 41  
42 **13.** Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in  
43  
44 pathogenesis, epidemiology and definition. *Seminars in neonatology : SN*.  
45  
46 2003-Feb 2003;8(1):63-71.  
47  
48
- 49  
50 **14.** Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia,  
51  
52 brain injury, and severe retinopathy on the outcome of extremely low-birth-weight  
53  
54

- 1  
2  
3 infants at 18 months - Results from the trial of indomethacin prophylaxis in  
4  
5  
6 preterms. *Jama-Journal of the American Medical Association*. Mar 5  
7  
8  
9 2003;289(9):1124-1129.
- 10  
11 **15.** Kim JN, Namgung R, Chang W, et al. Prospective evaluation of perinatal risk  
12  
13 factors for cerebral palsy and delayed development in high risk infants. *Yonsei*  
14  
15  
16 *Medical Journal*. Aug 1999;40(4):363-370.
- 17  
18  
19 **16.** Van Marter LJ, Kuban KCK, Allred E, et al. Does bronchopulmonary dysplasia  
20  
21 contribute to the occurrence of cerebral palsy among infants born before 28  
22  
23 weeks of gestation? *Archives of Disease in Childhood-Fetal and Neonatal Edition*.  
24  
25  
26 Jan 2011;96(1):F20-F29.
- 27  
28  
29 **17.** Bashir RA, Bhandari V, Vayaltrikkovil S, et al. Chorioamnionitis at birth does not  
30  
31 increase the risk of neurodevelopmental disability in premature infants with  
32  
33 bronchopulmonary dysplasia. *Acta Paediatr*. Nov 2016;105(11):e506-e512.
- 34  
35  
36  
37 **18.** Wang L-W, Lin Y-C, Wang S-T, Yeh T-F, Huang C-C, Taiwan Premature Infant  
38  
39 Dev C. Hypoxic/Ischemic and Infectious Events Have Cumulative Effects on the  
40  
41 Risk of Cerebral Palsy in Very-Low-Birth-Weight Preterm Infants. *Neonatology*.  
42  
43  
44 2014 2014;106(3):209-215.
- 45  
46  
47 **19.** Zhu T, Tang J, Zhao F, Qu Y, Mu D. Association between maternal obesity and  
48  
49 offspring Apgar score or cord pH: a systematic review and meta-analysis. *Sci Rep*.  
50  
51  
52 Dec 22 2015;5:18386.
- 53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4 **20.** Hartzel J, Agresti A, Caffo B. Multinomial logit random effects models. *Statistical*  
5  
6 *Modelling*. Jul 2001;1(2):81-102.  
7
- 8 **21.** Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in  
9  
10 meta-analyses. *Bmj*. Sep 06 2003;327(7414):557-560.  
11  
12
- 13 **22.** Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected  
14  
15 by a simple, graphical test. *Bmj*. Sep 13 1997;315(7109):629-634.  
16  
17
- 18 **23.** Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for  
19  
20 publication bias. *Biometrics*. Dec 1994;50(4):1088-1101.  
21  
22
- 23 **24.** Schlapbach LJ, Ersch J, Adams M, Bernet V, Bucher HU, Latal B. Impact of  
24  
25 chorioamnionitis and preeclampsia on neurodevelopmental outcome in preterm  
26  
27 infants below 32 weeks gestational age. *Acta Paediatrica*. Oct  
28  
29 2010;99(10):1504-1509.  
30  
31
- 32 **25.** Tran U, Gray PH, O'Callaghan MJ. Neonatal antecedents for cerebral palsy in  
33  
34 extremely preterm babies and interaction with maternal factors. *Early Human*  
35  
36 *Development*. Jun 2005;81(6):555-561.  
37  
38
- 39 **26.** Synnes A, Luu TM, Moddemann D, et al. Determinants of developmental  
40  
41 outcomes in a very preterm Canadian cohort. *Archives of Disease in*  
42  
43 *Childhood-Fetal and Neonatal Edition*. May 2017;102(3):F235-F243.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

- 1  
2  
3  
4 **27.** Natarajan G, Pappas A, Shankaran S, et al. Outcomes of extremely low birth  
5  
6 weight infants with bronchopulmonary dysplasia: Impact of the physiologic  
7  
8 definition. *Early Human Development*. Jul 2012;88(7):509-515.  
9
- 10  
11 **28.** Gagliardi L, Bellu R, Zanini R, Dammann O. Bronchopulmonary dysplasia and  
12  
13 brain white matter damage in the preterm infant: A complex relationship.  
14  
15 *Paediatric and Perinatal Epidemiology*. November 2009;23(6):582-590.  
16  
17
- 18  
19 **29.** Lodha A, Sauve R, Tand S, Singhal N. Does advanced maternal age affect long  
20  
21 term neuro developmental outcomes in preterm infants at 3 years of age?  
22  
23 *Paediatrics and Child Health*. June-July 2011;16:33A.  
24  
25
- 26  
27 **30.** Palta M, Sadeh-Badawi M, Evans M, Weinstein MR, McGuinness G, Newborn  
28  
29 Lung P. Functional assessment of a multicenter very low-birth-weight cohort at  
30  
31 age 5 years. *Archives of Pediatrics & Adolescent Medicine*. Jan  
32  
33 2000;154(1):23-30.  
34  
35
- 36  
37 **31.** Gallini F, Arena R, Stella G, Frezza S, Maggio L. Neurodevelopmental outcomes  
38  
39 of premature infants with bronchopulmonary dysplasia. *Acta bio-medica : Atenei*  
40  
41 *Parmensis*. 2014 Jun 2014;85(1):30-34.  
42  
43
- 44  
45 **32.** Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of  
46  
47 postnatal systemic corticosteroids on mortality and cerebral palsy in preterm  
48  
49 infants: Effect modification by risk for chronic lung disease. *Pediatrics*. Mar  
50  
51 2005;115(3):655-661.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 **33.** Shankaran S, Johnson Y, Langer JC, et al. Outcome of extremely-low-birth-weight  
5  
6 infants at highest risk: Gestational age  $\leq$  24 weeks, birth weight  $\leq$  750 g, and  
7  
8 1-minute Apgar  $\leq$  3. *American Journal of Obstetrics and Gynecology*. Oct  
9  
10 2004;191(4):1084-1091.  
11  
12
- 13 **34.** Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte  
14  
15 progenitors to hypoxia-ischemia. *J Neurosci*. Jan 2002;22(2):455-463.  
16  
17
- 18 **35.** Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal  
19  
20 white matter in premature birth. *Stroke*. Feb 2007;38(2 Suppl):724-730.  
21  
22
- 23 **36.** Back SA, Rosenberg PA. Pathophysiology of glia in perinatal white matter injury.  
24  
25  
26 *Glia*. Nov 2014;62(11):1790-1815.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1. Characteristics of the included studies.**

Study	Publication year	country	Study design	Gestational age/ birth weight	Sample size	BPD definition	Primary outcome	adjusted confounder variables
Gagliardi <sup>28</sup>	2009	Italy	Cohort study	<32 weeks and BW<1500g	1209	BPD (at 36 weeks PMA)	ORs=2.16(CI, 1.1-3.9)	GA, propensity score for prolonged ventilation, centre
Kim <sup>15</sup>	1999	Korea	Case-control	<37 weeks	184	BPD (oxygen dependence at 28 days)	ORs=1.12(CI, 0.85-1.5)	Apgar score at 5 min, IVH, PDA, sepsis, duration of mechanical ventilation
Lodha <sup>29</sup>	2011	Canada	Cohort study	<28 weeks	918	NA	ORs=2(CI, 1.2-3.2)	NA
Natarajan <sup>27</sup>	2012	NA	Cohort study	<27 weeks BW<1000g	1189	BPD (at 36 weeks PMA)	ORs=2.41(CI, 1.4-4.13)	GA, male gender, SGA, maternal education, surgical NEC, IVH or PVL
Palta <sup>30</sup>	2000	USA	Cohort study	BW<1500g	1024	Severe BPD	ORs=2.3(CI, 1.2-4.6)	NA
Schlapbach <sup>24</sup>	2010	Switzerland	Case-control study	<32 weeks	99	BPD (at 36 weeks PMA)	ORs=3.75(CI, 1.08-11.14)	gestational age, birth weight, postnatal growth, mechanical ventilation
Synnes <sup>26</sup>	2017	Canada	Cohort study	<29 weeks	3700	BPD (at 36 weeks PMA)	ORs=1.42(CI, 1.17-1.73)	NA
Tran <sup>25</sup>	2005	Australia	Case control	<27 weeks	150	NA home oxygen	ORs=3.4(CI, 1.2-9.4)	NA
Van Marter <sup>16</sup>	2011	USA	Cohort study	<28 weeks	1047	BPD (at 36 weeks PMA)	ORs=1.77(CI, 1.02-3.77) ORs=5.16(CI, 2.62-10.16)	NA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

						BPD (Mechanical ventilation at 36 weeks)		
Wang <sup>18</sup>	2014	China	Cohort study	GA<30 weeks and BW<1500g	5807	Not mentioned	ORs=3.14(CI, 2.61-3.85)	GA, BW, sex, ROP grade≥III, grade III/IV IVH and PVL
Bashir <sup>17</sup>	2016	Canada	Retrospective observational study	BW<1250g	1563	BPD (at 36 weeks PMA)	ORs=1.3(CI, 0.87-1.96)	GA, male gender, ANCS use, Apgar score<7 at 5 minutes, SGA, postnatal steroids, blood transfusion, PDA, IVH grade≥III and/ or PVL, ROP grade≥III and/ or required laser treatment and postnatal sepsis

For peer review only

**Table 2. Pooled results of the associations between bronchopulmonary dysplasia and cerebral palsy in children.**

Variables	Studies (n)	ORs(95%CI)	$I^2$ (p-value for heterogeneity)
Total	11	2.10(1.57,2.82)	82.5% (0.000)
Study design			
Case-control	3	2.13 (0.85, 5.34)	82.1% (0.000)
Cohort	8	2.15 (1.57, 2.94)	73.6% (0.023)
Definition of BPD			
Oxygen dependence at 36 weeks	6	1.67(1.33,2.11)	33.2% (0.187)
Oxygen dependence at 28 days	1	1.12(0.84,1.49)	NA
Severe BPD (mechanical ventilation)	2	3.44(1.56,7.60)	63.7%(0.097)
Not mentioned BPD type	3	2.80(2.08, 3.79)	30.5% (0.237)
Diagnostic criteria for cerebral palsy			
Age $\geq$ 2 years only	4	1.54(1.15,2.06)	62.4% (0.046)
Age<2 years included	6	2.31(1.61,3.32)	69.7% (0.006)
Controlling for potential confounders			
Unadjusted estimates	5	2.01(1.43,2.83)	53.4% (0.072)
Controlled for gestational age	5	2.29(1.50, 3.49)	74.3% (0.004)

NA: not available

**Figure captions**

Figure 1. Flow chart for study selection

Figure 2. Analysis of BPD and CP.

Figure 3. The Egger's test for publication bias test.

Figure 4. The Begg's test for publication bias test.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart for study selection

190x113mm (300 x 300 DPI)

Review only






Figure 2. Analysis of BPD and CP.

190x172mm (300 x 300 DPI)




Figure 3. The Egger's test for publication bias test.

190x126mm (300 x 300 DPI)

view only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. The Begg's test for publication bias test.

190x126mm (300 x 300 DPI)

view only

1  
2  
3  
4  
5  
6  
7 **The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis**

8  
9 **Supplement 1. Retrieval strategy of PubMed, EMBASE and Web of Science**

10 Before 1 September 2017.

11  
12  
13 **PubMed 195**

14 Search (((((((Cerebral pals\*[Title/Abstract]) OR CP[Title/Abstract]) OR spastic\*[Title/Abstract]) OR Cerebral Palsy[Title/Abstract])) OR  
15 "Cerebral Palsy"[Mesh])) AND (((((((Dysplasia, Bronchopulmonary[Title/Abstract]) OR Bronchopulmonary Dysplasia[Title/Abstract]) OR  
16 BPD[Title/Abstract]) OR bronchopulmonary dysplasia[Title/Abstract])) OR "Bronchopulmonary Dysplasia"[Mesh])

17  
18  
19 **EMBASE 523**

20 Before 1 September 2017.

21  
22 1 Cerebral palsy/  
23

24 2 Cerebral pals\$.tw.  
25

26 3 Little\$ disease.tw.  
27

28 4 CP.tw.  
29

30 5 (unilateral adj3 spastic\$.tw.  
31

32 6 (hemiplegi\$ adj3 spastic\$.tw.  
33

34 7 (diplegi\$ adj3 spastic\$.tw.  
35

36 8 (tetrapleg\$ adj3 spastic\$.tw.  
37

38 9 (triplegi\$ adj3 spastic\$.tw.  
39  
40  
41  
42  
43  
44  
45  
46  
47

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

10 ((bilateral or bi-lateral) adj3 spastic\$.tw.

11 (quadripleg\$ adj3 spastic\$.tw.

12 or/1-11

13 Bronchopulmonary Dysplasia.mp. or exp lung dysplasia/

14 BPD.tw.

15 Dysplasia, Bronchopulmonary.tw.

16 Bronchopulmonary Dysplasia.tw.

17 13 or 14 or 15 or 16

18 12 and 17

### Web of science 515

Before 1 September 2017.

TS=(cerebral pals\* or spastic\* or quadripleg\* or cerebral palsy or CP)

TS=(Bronchopulmonary Dysplasia or lung dysplasia or bronchopulmonary dysplasia or BPD or Dysplasia, Bronchopulmonary)

**Supplement 2. Newcastle - Ottawa Quality Assessment Scale results for case-control studies**

Question	Option	Kim	Schlapbach	Tran
Is the case definition adequate?	a) yes, with independent validation * b) yes, eg record linkage or based on self reports c) no description	a	a	a
Representativeness of the cases	a) consecutive or obviously representative series of cases * b) potential for selection biases or not stated	a	b	b
Selection of Controls	a) community controls * b) hospital controls c) no description	b	b	b
Definition of Controls	a) no history of disease (endpoint)* b) no description of source	a	a	b
Comparability of cases and controls on the basis of the design or analysis	a) study controls for (Select the most important factor.* b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) *	a	a	a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

<p>Ascertainment of exposure</p>	<p>a) secure record (eg surgical records)*  b) structured interview where blind to case/control status*  c) interview not blinded to case/control status  d) written self report or medical record only  e) no description</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Same method of ascertainment for cases and controls</p>	<p>a) yes*  b) no</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Non-Response rate</p>	<p>a) same rate for both groups*  b) non-respondents described  c) rate different and no designation</p>	<p>b</p>	<p>a</p>	<p>b</p>

For peer review only

Supplement 3. Newcastle - Ottawa Quality Assessment Scale results for cohort studies

Question	Option	Gagliardi	Lodha	Palta	Natarajan	Synnes	Van Marter	Wang	Bahir
Representativeness of the exposed cohort	a) truly representative of the average (describe) in the community * b) somewhat representative of the average in the community* c) selected group of users eg nurses, volunteered) no description of the derivation of the cohort	b	b	b	b	b	b	b	b
Selection of the Non-exposed cohort	a) drawn from the same community as the exposed cohort* b) drawn from a different source c) no description of the derivation of the non-exposed cohort	a	a	a	a	a	a	a	a
Ascertainment of exposure	a) secure record (eg surgical records)* b) structured interview* c) written self report d) no description	a	a	a	a	b	a	a	a
Demonstration that outcome of interest was not present at start of study	a) yes* b) no	a	a	a	a	a	a	a	a
Comparability of cohorts on the basis of the design or analysis	a) study controls for (select the most important factor)* b) study controls for any additional factor*	a	a	a	a	a	a	a	a



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Assessment of outcome	a) independent blind assessment* b) record linkage* c) self report d) no description	b	b	b	b	b	b	b	b
Was follow-up long enough for outcomes to occur	a) yes* b) no	b	b	b	a	a	a	a	a
Adequacy of follow up of cohort	a) complete follow up - all subjects accounted for* b) subjects lost to follow up unlikely to introduce bias - small number lost - > % (select an adequate %) follow up, or description provided of those lost c) follow up rate < % (select an adequate %) and no description of those lost d) no statement	d	d	d	d	d	d	d	d

#### Supplement 4. Egger's and Begg's test for publication bias test

##### Begg's Test

adj. Kendall's Score (P-Q) = 6

Std. Dev. of Score = 9.59

Number of Studies = 9

$z = 0.63$

$\text{Pr} > |z| = 0.532$

$z = 0.52$  (continuity corrected)

$\text{Pr} > |z| = 0.602$  (continuity corrected)

##### Egger's test

Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
slope	.1683662	.139195	1.21	0.266	-.1607777	.49751
bias	-.8435039	.608102	-1.39	0.208	-2.281437	.5944288

# BMJ Open

## The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020735.R1
Article Type:	Research
Date Submitted by the Author:	17-Apr-2018
Complete List of Authors:	Gou, Xiaoyun; West China Second University Hospital, Sichuan University, Chengdu 610041, China Yang, Lei; West China Second University Hospital, Sichuan University, Chengdu 610041, China Pan, Lingli; West China Second University Hospital, Sichuan University, Chengdu 610041, China Xiao, Dongqiong; West China Second University Hospital, Sichuan University, Chengdu 610041, China
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Neurology
Keywords:	bronchopulmonary dysplasia, cerebral palsy, neurodevelopment, infant

SCHOLARONE™  
Manuscripts

Peer Review Only

1  
2  
3 **The association between bronchopulmonary dysplasia and cerebral**  
4 **palsy in children: A meta-analysis**  
5  
6

7 Xiaoyun Gou<sup>1,2#</sup>, Lei Yang<sup>1,2#</sup>, Lingli Pan<sup>1,2</sup>, Dongqiong Xiao<sup>1,2\*</sup>  
8  
9

10 <sup>1</sup>Department of Pediatrics, West China Second University Hospital, Sichuan University,  
11 Chengdu 610041, China  
12  
13

14 <sup>2</sup>Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan  
15 University), Ministry of Education, Chengdu 610041, China  
16  
17

18 # These authors contributed equally to the study.  
19  
20

21 **\*Corresponding author**  
22  
23

24 **Dongqiong Xiao, MD**  
25  
26

27 Department of Pediatrics,  
28

29 West China Second University Hospital,  
30

31 Sichuan University, Chengdu, Sichuan 610041, China  
32  
33

34 Email: m13881749494@163.com  
35  
36

37 Telephone: +86-28-85502273  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To investigate the association between bronchopulmonary dysplasia (BPD) and the risk of cerebral palsy (CP) in children.

**Data sources** We used EMBASE, PubMed and Web of Science to conduct a meta-analysis of studies published before September 1 2017, written in English which titles or abstracts discussed an association between BPD and CP.

**Study selection:** Observational studies eg case control and cohort studies were included.

**Data extraction and synthesis:** All review stages were conducted by 2 reviewers independently. Data synthesis was undertaken via meta-analysis of available evidence.

**Main outcomes and measures:** The prevalence of developing CP was measured after exposure to BPD.

**Results** Among 1234 initially identified studies, we selected those that addressed an association between BPD and CP according to our preselected inclusion criteria. Our meta-analysis included 11 studies. According to a random effect model, BPD was significantly associated with cerebral palsy (ORs, 2.10; 95% CI, 1.57, 2.82) in preterm infants. Factors explaining differences in the study results included study design, the definition of BPD, the time of diagnosis of CP, and whether the studies adjusted for potential confounders.

**Conclusion** This study suggests that BPD is a risk factor for cerebral palsy. Further studies are required to confirm these results and to detect the influence of variables across studies.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** bronchopulmonary dysplasia; cerebral palsy; neurodevelopment; infant

For peer review only

### Strengths and limitations of the study

\*No consensus exists regarding the association between BPD and CP in children.

\*The clear and univocal definition of BPD may explain the differences of the results of studies which evaluated the association between BPD and CP in children.

\*The number of studies included is limited, and therefore, the results of the meta-analysis should be interpreted with caution.

\*Observational study designs rarely can establish causality.

## Introduction

Despite advances in obstetric and neonatal care, the prevalence of developing cerebral palsy (CP) was approximately at 0.2% during the past decades<sup>1</sup>, and the etiology of CP remains poorly understood. Evidence shows that prenatal factors, including maternal age<sup>2</sup>, education<sup>3 4</sup>, obesity<sup>5-7</sup>, race<sup>8</sup>, chorioamnionitis<sup>1</sup> and hypertension<sup>9</sup> contribute to CP.

Bronchopulmonary dysplasia (BPD) has been implicated as a potential neonatal factor of CP<sup>10</sup>. BPD is common in preterm and low birthweight infants born at 24 to 26 weeks of gestation<sup>11</sup>. The lung is in the canalicular stage from 16 to 28 weeks, and it is in the saccular stage from 28 to 36 weeks. Alveoli are not uniformly present until 36 weeks. Thus, premature birth and the initiation of pulmonary gas exchange arrest normal alveolar and distal vascular development, and subsequent BPD<sup>11</sup>. Maternal infection, especially maternal chorioamnionitis was associated with an increased risk of BPD<sup>12</sup>. The inconsistencies in the definition of BPD contribute to variation in incidence of BPD. BPD is a chronic lung disease developed after mechanical ventilation or oxygen inhalation usually occurring in certain premature neonates with respiratory distress syndrome. Some studies defined as oxygen dependency at 36 weeks post-menstrual age (PMA), yet, others defined as 28 or more days duration of oxygen dependency during hospitalization<sup>12</sup>. Cerebral palsy, cognitive delay, and hearing loss are important and commonly reported adverse outcomes in very premature infants<sup>13</sup>. It is postulated that BPD can lead to neonatal brain injury and subsequent CP<sup>14</sup>.

A number of studies have assessed the relationship between BPD and CP in premature infants, the association between BPD and CP was inconsistent. Some of the studies have not examined a significant association<sup>15 16</sup>. For example, one study defined BPD as 28 days duration of oxygen dependency<sup>15</sup> and reported insignificant



1  
2  
3 association between BPD and CP, additionally, another study<sup>14</sup> evaluated the  
4 association between BPD (oxygen dependency at 36 weeks) and quadriparesis and  
5 diparesis, and reported the same result. However, any other studies<sup>17 18</sup> showed a  
6 significant association between BPD and CP. We conducted a meta-analysis to  
7 evaluate the potential association between BPD and CP in preterm infants.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Methods

**Retrieval of studies.** The PubMed, EMBASE, and Web of Science databases were searched through September 1, 2017. The search of bronchopulmonary dysplasia was performed using the following keywords and subject terms: “bronchopulmonary dysplasia”, or “BPD\*”, or “lung dysplasia”, or “Dysplasia, Bronchopulmonary”, or “Bronchopulmonary Dysplasia”, using “OR” to link relevant text within the search field. To acquire studies related to cerebral palsy, “OR” was used to associate the key words, which included “cerebral palsy”, “Crebral pals\*”, “spastic\*”, “quadripleg\*” and “CP”. We combined these terms using “AND” to retrieve the studies (Supplement 1). We restricted the search to human studies published in English. The retrieved studies were screened by reading the titles and abstracts, and two authors (Xiaoyun Gou and Lei Yang) subsequently read the full text of the remaining publications independently and then discussed disagreements to reach a consensus.

**Patient and Public Involvement.** Not required, a meta-analysis

**Study selection.** The study inclusion criteria were as follows: (1) the study evaluated the association between bronchopulmonary dysplasia (BPD) and the risk of CP in children; (2) the study was published in English; (3) case-control or cohort study design; (4) the study described the assessment of exposure and outcome, the relevant exposure included any type of BPD. Relevant outcome included any definition of CP. The association between exposure and outcome was directly reported by unadjusted and/or adjusted relative ratios (RRs) and corresponding 95% confidence intervals (CIs), unadjusted and/or adjusted odds ratios (ORs) estimates and 95% CIs.

The exclusion criteria were as follows: (1) a review or meta-analysis or a case report; (2) the study was not published in English; (3) the article described an animal experiment study; (4) a study with overlapping data; (5) the articles with unusable

1  
2  
3 data that was reported that have allowed RRs/ORs to be calculated (e.g. number of  
4 cases of BPD events and total number of children with CP).  
5  
6

7  
8 **Data extraction.** The data were independently extracted from the studies by two  
9 reviewers (Xiaoyun Gou and Lei Yang) and included the name of the first author,  
10 publication year, the country of the participants, study design, sample size, gestational  
11 age and/or birthweight, following years, BPD definition, primary outcome (the  
12 association between BPD and risk of CP), and adjusted confounders.  
13  
14  
15  
16

17  
18 **Quality evaluation.** The two reviewers (Xiaoyun Gou and Lei Yang) independently  
19 used the Newcastle-Ottawa Scale (NOS)<sup>19</sup> to examine all included studies for their  
20 methodological quality. The reviewers evaluated the quality score via examine the  
21 selection of the study population, comparability and evaluation of exposure and  
22 outcome, with a maximum score of nine. The reviewers resolved disagreements in the  
23 manner previously described.  
24  
25  
26  
27  
28  
29

30  
31 **Statistical analysis.** The original studies included used ORs and/or RRs and 95% CIs to  
32 assess the association between BPD and the risk of CP in children. The ORs and RRs  
33 were directly considered as ORs when the outcome is rare<sup>1</sup>. We pooled ORs and/or  
34 RRs of each study separately using the Der Simonian-Laird formula (random-effects  
35 model)<sup>20</sup>. Statistical heterogeneity<sup>21</sup> between the studies was assessed using the Q  
36 and  $I^2$  statistics. Values of  $I^2 > 50\%$  and  $P < 0.1$  indicated high heterogeneity<sup>1</sup>. We  
37 conducted a stratified analysis based on study design (case-control, cohort), BPD type  
38 (oxygen dependency at 36 weeks' post-menstrual age (PMA), 28 days duration of  
39 oxygen dependency during hospitalization, severe BPD including mechanical  
40 ventilation at 36 weeks, not defined BPD), diagnostic criteria for CP (Age <2 years,  
41 other), confounding variables (gestational age, unadjusted estimated).  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 We used Egger's<sup>22</sup> and Begg's<sup>23</sup> tests to assess the publication bias, which was  
53 considered to be statistically significant when  $p < 0.05$ . We used Stata software,  
54  
55

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

version 12.0 (Stata Corp, College Station, TX) to perform the statistical tests.

For peer review only

## Results

**Literature search.** We identified 1234 potential studies: 195 from PubMed, 523 from EMBASE, 515 from Web of Science and 1 additional study from the related reference. After careful screening, 11 studies that reported the association between BPD and the risk of CP in children were selected for inclusion in this study (see Figure 1). These 11 included studies are summarized in Table 1.

**Characteristics and quality of the included studies.** The included studies were published between 1999 and 2017. Eleven studies evaluated the association between BPD and cerebral palsy in preterm infants. Two<sup>15 16</sup> of these studies reported no significant association. Eight of the included studies were cohort studies and three<sup>15 17 18</sup> of the studies were case-control studies of a high quality (NOS>5, Supplement 2, Supplement 3). All the studies evaluated the association between BPD and CP in preterm neonates with ORs.

**Bronchopulmonary dysplasia (BPD) and cerebral palsy (CP).** When the study results were analyzed using random effects model, BPD was significantly associated with CP (Figure 2). These infants were preterm infants.

**Stratified analysis.** A stratified analysis was conducted to determine whether there are any significantly different results across the subgroups considered (Table 2). The case-control studies did not produce significant summary ORs (2.13; 95%CI, 0.85, 5.34,  $I^2=82.1\%$ ), yet, a significant association was seen in cohort studies ORs (2.15; 95%CI, 1.57, 2.94,  $I^2=73.6\%$ ).

Six studies<sup>14 16 18 24-26</sup> evaluated the association between BPD (oxygen dependence at 36 weeks) and CP in premature infants, with only 1 reporting<sup>16</sup> a no significant association (Figure 2). One study<sup>15</sup> evaluated the association between BPD

1  
2  
3 (oxygen dependence at 28 days) and CP in premature infants with no significant  
4 association (OR 1.12, 95%CI, 0.84, 1.49). Three studies<sup>17 27 28</sup> evaluated the  
5 association (OR 2.80, 95%CI, 2.08, 3.79,  $I^2=30.5%$ ) without mentioned BPD  
6 definition, and 2 studies<sup>14 29</sup> show severe BPD or mechanical ventilation at 36 weeks  
7 (OR 3.44, 95%CI, 1.56, 7.60,  $I^2=63.7%$ ).  
8  
9  
10  
11  
12

13 The definition of CP differed greatly among studies of preterm infants (Table 2).  
14 Of the four studies<sup>14 16 24 28</sup> that provided adequate information, four studies provided  
15 a minimum age of 2 years for diagnosing CP; Some studies confirm the diagnosis by  
16 performing examination, while others did not. Some studies excluded children with  
17 congenital anomalies<sup>15 16 28</sup>, while others<sup>14 24</sup> did not specify any exclusion criteria.  
18  
19  
20  
21  
22

23 Five studies of BPD(PMA) in premature infants reported ORs controlled for  
24 gestational age. Association between BPD and CP remains significant both adjusted  
25 or unadjusted by gestational age (ORs, 2.29; 95%CI, 1.5, 3.49; vs ORs, 2.01; 1.43,  
26 2.83; Table 2).  
27  
28  
29  
30

31 **Publication bias.** Asymmetry and publication bias were evaluated by Egger's and  
32 Begg's tests (Figure 3, Figure 4). The pooled results did not support the presence of  
33 significant publication bias (all  $p>0.05$ , Supplement 4).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

To our knowledge, this article is the first meta-analysis of the relationship between BPD and risk of CP in children. The results of this meta-analysis, which included 11 studies, showed evidence that BPD appears to be associated with CP in preterm infants.

BPD might affect the neurodevelopment outcome of infants through multiple pathways. A growing body evidence supports that BPD contributes to neonatal brain injury<sup>30</sup>. Experimental BPD with hypoxia leads to central nervous system damage, and subsequent CP<sup>31 32</sup>. Indeed, the preterm infants with BPD accompany with hypoxia often had oligodendrocytes maturation arrest or injury<sup>33-35</sup>, disruption of myelination and demyelination, and then cause white matter injury<sup>35</sup> and impaired neurodevelopmental outcomes<sup>32</sup>.

To better understand the relationship between BPD and CP, it is crucial to develop consensus definitions of BPD. Most published reports do not apply specific diagnostic criteria for BPD, as a group, these studies produced heterogeneous results. The results of the stratified analysis suggest that a stronger association is seen when used severe or mechanical ventilation at 36 weeks diagnostic criteria in the studies. The studies do not include strict criteria may lead to an over-diagnosis of BPD, which may contribute to the evidence of heterogeneity.

The definition of CP varied between studies; although CP can be difficult to diagnosis in children younger than 2 years, 1 study made the diagnosis in infants younger than 12 months. A consensus definition of CP is required.

Some studies report significant associations between BPD and CP after adjust for potential confounders<sup>15 16 18 25 26 28</sup>. Although gestational age appears to be a possible

1  
2  
3 confounder, it may not lie directly in the causal pathway between BPD and CP.  
4  
5 Gestational age can be considered as a confounder, as a premature baby is born at any  
6  
7 gestational age and a lot of time later may develop BPD. The study would falsely  
8  
9 diminish the association between BPD and CP without considering gestational age as  
10  
11 a confounder. BPD is associated with premature delivery, and low gestational age,  
12  
13 which is associated with a host of intrinsic vulnerabilities within the brain, that have  
14  
15 been implicated in the pathogenesis of CP. Therefore, if low gestational age resulting  
16  
17 in BPD plays a direct role in the pathogenesis of CP, then adjusting for gestational age  
18  
19 will falsely diminish the observed association between BPD and CP. One study<sup>16</sup> of  
20  
21 BPD in premature infants found no association when controlling for the confounder  
22  
23 variables including gestational age. It is unclear if this is because BPD does not  
24  
25 contribute independently to CP, or perhaps because gestational age lies on the causal  
26  
27 pathway.

28  
29 Other factors may interact with BPD in the pathogenetic pathway leading to CP.  
30  
31 For example, child sex, IVH, Apgar score at 5 minutes, small for gestational age  
32  
33 (SGA), which may contribute to CP lies on the causal pathway. Accordino et al.<sup>36</sup>  
34  
35 demonstrated that premature spontaneous birth and iatrogenic preterm birth are  
36  
37 significantly associated with CP. The reasons of the difference contribute to  
38  
39 neurological damage would be related to infection. Although the studies controlled for  
40  
41 some confounder variables, many other factors that contribute to CP may not be  
42  
43 excluded.

44  
45 Our meta-analysis is subject to limitations as follows. Firstly, we only included  
46  
47 articles published in English. Secondly, there may be publication bias, incomplete  
48  
49 ascertainment of published studies, and errors in data abstraction. Thirdly, the number  
50  
51 of studies included is small, and therefore, the results of this meta-analysis should be  
52  
53  
54



1  
2  
3 interpreted with caution. Furthermore, the bias inherent to observational studies are  
4 not eliminated in a quantitative synthesis.  
5  
6

7  
8 Our meta-analysis has some merits. First, the study evaluated the association  
9 between BPD and CP. Second, the study used stratified analysis to explore the  
10 heterogeneity source, and the different definition of BPD may contribute to the source  
11 of heterogeneity.  
12  
13  
14

15  
16 In conclusion, our pooled analyses provide evidence that BPD is significantly  
17 associated with cerebral palsy in children. Future studies that consider additional  
18 factors are required to resolve this issue.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

### **Author contributions**

XG and LY contributed to the conception and design of the study, as well as to the drafting of this article. LP contributed to the collection and analysis of the data. DX contributed to the conception and design of the study and approved the final version of the manuscript for submission for publication.

### **Funding**

No financial support for this work

### **Ethical approval**

Not available, a meta-analysis

### **Competing financial interests**

The authors declare that they have no competing financial interests.

### **Data sharing statement**

No additional data are available.

## References

1. Wu YW, Colford JM, Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. *Jama* 2000;284(11):1417-24. [published Online First: 2000/09/16]
2. Pan C, Deroche CB, Mann JR, et al. Is prepregnancy obesity associated with risk of cerebral palsy and epilepsy in children? *J Child Neurol* 2014;29(12):Np196-201. doi: 10.1177/0883073813510971 [published Online First: 2013/12/18]
3. Villamor E, Tedroff K, Peterson M, et al. Association Between Maternal Body Mass Index in Early Pregnancy and Incidence of Cerebral Palsy. *Jama* 2017;317(9):925-36. doi: 10.1001/jama.2017.0945 [published Online First: 2017/03/08]
4. Persson M, Johansson S, Villamor E, et al. Maternal overweight and obesity and risks of severe birth-asphyxia-related complications in term infants: a population-based cohort study in Sweden. *PLoS Med* 2014;11(5):e1001648. doi: 10.1371/journal.pmed.1001648 [published Online First: 2014/05/23]
5. Wang Y, Tang S, Xu S, et al. Maternal Body Mass Index and Risk of Autism Spectrum Disorders in Offspring: A Meta-analysis. *Sci Rep* 2016;6:34248. doi: 10.1038/srep34248 [published Online First: 2016/10/01]
6. Crisham Janik MD, Newman TB, Cheng YW, et al. Maternal diagnosis of obesity and risk of cerebral palsy in the child. *J Pediatr* 2013;163(5):1307-12. doi: 10.1016/j.jpeds.2013.06.062 [published Online First: 2013/08/13]

- 1  
2  
3  
4 7. Forthun I, Wilcox AJ, Strandberg-Larsen K, et al. Maternal Prepregnancy BMI and Risk of  
5  
6 Cerebral Palsy in Offspring. *Pediatrics* 2016;138(4) doi: 10.1542/peds.2016-0874  
7  
8 [published Online First: 2016/09/10]  
9  
10  
11 8. Bear JJ, Wu YW. Maternal Infections During Pregnancy and Cerebral Palsy in the Child.  
12  
13 *Pediatr Neurol* 2016;57:74-9. doi: 10.1016/j.pediatrneurol.2015.12.018 [published  
14  
15 Online First: 2016/02/10]  
16  
17  
18 9. Kronenberg ME, Raz S, Sander CJ. Neurodevelopmental outcome in children born to  
19  
20 mothers with hypertension in pregnancy: the significance of suboptimal intrauterine  
21  
22 growth. *Developmental Medicine and Child Neurology* 2006;48(3):200-06. doi:  
23  
24 10.1017/s0012162206000430  
25  
26  
27  
28 10. Bregman J, Farrell EE. NEURODEVELOPMENTAL OUTCOME IN INFANTS WITH  
29  
30 BRONCHOPULMONARY DYSPLASIA. *Clinics in Perinatology* 1992;19(3):673-94.  
31  
32  
33 11. Coalson JJ. Pathology of new bronchopulmonary dysplasia. *Seminars in neonatology : SN*  
34  
35 2003;8(1):73-81. doi: 10.1016/s1084-2756(02)00193-8  
36  
37  
38 12. Bancalari E, Claire N, Sosenko IRS. Bronchopulmonary dysplasia: changes in  
39  
40 pathogenesis, epidemiology and definition. *Seminars in neonatology : SN*  
41  
42 2003;8(1):63-71. doi: 10.1016/s1084-2756(02)00192-6  
43  
44  
45 13. Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia, brain  
46  
47 injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at  
48  
49 18 months - Results from the trial of indomethacin prophylaxis in preterms.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Jama-Journal of the American Medical Association* 2003;289(9):1124-29. doi:

10.1001/jama.289.9.1124

14. Van Marter LJ, Kuban KCK, Allred E, et al. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?

*Archives of Disease in Childhood-Fetal and Neonatal Edition* 2011;96(1):F20-F29. doi:

10.1136/adc.2010.183012

15. Kim JN, Namgung R, Chang W, et al. Prospective evaluation of perinatal risk factors for cerebral palsy and delayed development in high risk infants. *Yonsei Medical Journal*

1999;40(4):363-70.

16. Bashir RA, Bhandari V, Vayalthrikkovil S, et al. Chorioamnionitis at birth does not increase the risk of neurodevelopmental disability in premature infants with bronchopulmonary

dysplasia. *Acta Paediatr* 2016;105(11):e506-e12. doi: 10.1111/apa.13556 [published

Online First: 2016/08/24]

17. Tran U, Gray PH, O'Callaghan MJ. Neonatal antecedents for cerebral palsy in extremely preterm babies and interaction with maternal factors. *Early Human Development*

2005;81(6):555-61. doi: 10.1016/j.earhumdev.2004.12.009

18. Schlapbach LJ, Ersch J, Adams M, et al. Impact of chorioamnionitis and preeclampsia on neurodevelopmental outcome in preterm infants below 32 weeks gestational age. *Acta*

*Paediatrica* 2010;99(10):1504-09. doi: 10.1111/j.1651-2227.2010.01861.x

- 1  
2  
3  
4 19. Zhu T, Tang J, Zhao F, et al. Association between maternal obesity and offspring Apgar  
5  
6 score or cord pH: a systematic review and meta-analysis. *Sci Rep* 2015;5:18386. doi:  
7  
8 10.1038/srep18386 [published Online First: 2015/12/23]  
9  
10  
11 20. Hartzel J, Agresti A, Caffo B. Multinomial logit random effects models. *Statistical Modelling*  
12  
13 2001;1(2):81-102. doi: 10.1177/1471082x0100100201  
14  
15  
16 21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.  
17  
18 *Bmj* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First:  
19  
20 2003/09/06]  
21  
22  
23  
24 22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,  
25  
26 graphical test. *Bmj* 1997;315(7109):629-34. [published Online First: 1997/10/06]  
27  
28  
29 23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication  
30  
31 bias. *Biometrics* 1994;50(4):1088-101. [published Online First: 1994/12/01]  
32  
33  
34 24. Synnes A, Luu TM, Moddemann D, et al. Determinants of developmental outcomes in a  
35  
36 very preterm Canadian cohort. *Archives of Disease in Childhood-Fetal and Neonatal*  
37  
38 *Edition* 2017;102(3):F235-F43. doi: 10.1136/archdischild-2016-311228  
39  
40  
41  
42 25. Natarajan G, Pappas A, Shankaran S, et al. Outcomes of extremely low birth weight  
43  
44 infants with bronchopulmonary dysplasia: Impact of the physiologic definition. *Early*  
45  
46 *Human Development* 2012;88(7):509-15. doi: 10.1016/j.earlhumdev.2011.12.013  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 26. Gagliardi L, Bellu R, Zanini R, et al. Bronchopulmonary dysplasia and brain white matter  
5  
6 damage in the preterm infant: A complex relationship. *Paediatric and Perinatal*  
7  
8 *Epidemiology* 2009;23(6):582-90.  
9  
10  
11 27. Lodha A, Sauve R, Tand S, et al. Does advanced maternal age affect long term neuro  
12  
13 developmental outcomes in preterm infants at 3 years of age? *Paediatrics and Child*  
14  
15 *Health* 2011;16:33A.  
16  
17  
18 28. Wang L-W, Lin Y-C, Wang S-T, et al. Hypoxic/Ischemic and Infectious Events Have  
19  
20 Cumulative Effects on the Risk of Cerebral Palsy in Very-Low-Birth-Weight Preterm  
21  
22 Infants. *Neonatology* 2014;106(3):209-15. doi: 10.1159/000362782  
23  
24  
25  
26 29. Palta M, Sadeh-Badawi M, Evans M, et al. Functional assessment of a multicenter very  
27  
28 low-birth-weight cohort at age 5 years. *Archives of Pediatrics & Adolescent Medicine*  
29  
30 2000;154(1):23-30.  
31  
32  
33  
34 30. Gallini F, Arena R, Stella G, et al. Neurodevelopmental outcomes of premature infants with  
35  
36 bronchopulmonary dysplasia. *Acta bio-medica : Atenei Parmensis* 2014;85(1):30-4.  
37  
38  
39 31. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids  
40  
41 on mortality and cerebral palsy in preterm infants: Effect modification by risk for  
42  
43 chronic lung disease. *Pediatrics* 2005;115(3):655-61. doi: 10.1542/peds.2004-1238  
44  
45  
46  
47 32. Shankaran S, Johnson Y, Langer JC, et al. Outcome of extremely-low-birth-weight infants  
48  
49 at highest risk: Gestational age <= 24 weeks, birth weight <= 750 g, and 1-minute  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4           Apgar <= 3. *American Journal of Obstetrics and Gynecology* 2004;191(4):1084-91.

5  
6           doi: 10.1016/j.ajog.2004.05.032

7  
8  
9       33. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors  
10  
11           to hypoxia-ischemia. *J Neurosci* 2002;22(2):455-63.

12  
13  
14       34. Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal white  
15  
16           matter in premature birth. *Stroke* 2007;38(2 Suppl):724-30. doi:

17  
18  
19           10.1161/01.STR.0000254729.27386.05

20  
21       35. Back SA, Rosenberg PA. Pathophysiology of glia in perinatal white matter injury. *Glia*  
22  
23           2014;62(11):1790-815. doi: 10.1002/glia.22658 [published Online First: 2014/03/31]

24  
25  
26       36. Accordino F, Consonni S, Fedeli T, et al. Risk factors for cerebral palsy in PPRM and  
27  
28           preterm delivery with intact membranes. *Journal of Maternal-Fetal & Neonatal*

29  
30           *Medicine* 2016;29(23):3854-59. doi: 10.3109/14767058.2016.1149562



**Table 1. Characteristics of the included studies.**

Study	Publication year	country	Study design	Gestational age/ birth weight	Sample size	BPD definition	Primary outcome	adjusted confounder variables	NOS score
Gagliardi <sup>26</sup>	2009	Italy	Cohort study	<32 weeks and BW<1500g	1209	BPD (at 36 weeks PMA)	ORs=2.16(CI, 1.1-3.9)	GA, propensity score for prolonged ventilation, centre	6
Kim <sup>15</sup>	1999	Korea	Case-control	<37 weeks	184	BPD (oxygen dependence at 28 days)	ORs=1.12(CI, 0.85-1.5)	Apgar score at 5 min, IVH, PDA, sepsis, duration of mechanical ventilation	7
Lodha <sup>27</sup>	2011	Canada	Cohort study	<28 weeks	918	NA	ORs=2(CI, 1.2-3.2)	NA	6
Natarajan <sup>25</sup>	2012	NA	Cohort study	<27 weeks BW<1000g	1189	BPD (at 36 weeks PMA)	ORs=2.41(CI, 1.4-4.13)	GA, male gender, SGA, maternal education, surgical NEC, IVH or PVL	7
Palta <sup>29</sup>	2000	USA	Cohort study	BW<1500g	1024	Severe BPD	ORs=2.3(CI, 1.2-4.6)	NA	6
Schlapbach <sup>18</sup>	2010	Switzerland	Case-control study	<32 weeks	99	BPD (at 36 weeks PMA)	ORs=3.75(CI, 1.08-11.14)	gestational age, birth weight, postnatal growth, mechanical ventilation	7
Synnes <sup>24</sup>	2017	Canada	Cohort study	<29 weeks	3700	BPD (at 36 weeks PMA)	ORs=1.42(CI, 1.17-1.73)	NA	8
Tran <sup>17</sup>	2005	Australia	Case control	<27 weeks	150	NA home oxygen	ORs=3.4(CI, 1.2-9.4)	NA	6
Van Marter <sup>14</sup>	2011	USA	Cohort study	<28 weeks	1047	BPD (at 36 weeks PMA) BPD (Mechanical ventilation at	ORs=1.77(CI, 1.02-3.77) ORs=5.16(CI, 2.62-10.16)	NA	8

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

						36 weeks)			
Wang <sup>28</sup>	2014	China	Cohort study	GA<30 weeks and BW<1500g	5807	Not mentioned	ORs=3.14(CI, 2.61-3.85)	GA, BW, sex, ROP grade≥III, grade III/IV IVH and PVL	8
Bashir <sup>16</sup>	2016	Canada	Retrospective observational study	BW<1250g	1563	BPD (at 36 weeks PMA)	ORs=1.3(CI, 0.87-1.96)	GA, male gender, ANCS use, Apgar score<7 at 5 minutes, SGA, postnatal steroids, blood transfusion, PDA, IVH grade≥III and/ or PVL, ROP grade≥III and/ or required laser treatment and postnatal sepsis	8

For peer review only

**Table 2. Pooled results of the associations between bronchopulmonary dysplasia and cerebral palsy in children.**

Variables	Studies (n)	ORs(95%CI)	$I^2$ (p-value for heterogeneity)
Total	11	2.10(1.57,2.82)	82.5% (0.000)
Study design			
Case-control	3	2.13 (0.85, 5.34)	82.1% (0.000)
Cohort	8	2.15 (1.57, 2.94)	73.6% (0.023)
Definition of BPD			
Oxygen dependence at 36 weeks	6	1.67(1.33,2.11)	33.2% (0.187)
Oxygen dependence at 28 days	1	1.12(0.84,1.49)	NA
Severe BPD (mechanical ventilation)	2	3.44(1.56,7.60)	63.7%(0.097)
Not mentioned BPD type	3	2.80(2.08, 3.79)	30.5% (0.237)
Diagnostic criteria for cerebral palsy			
Age $\geq$ 2 years only	4	1.54(1.15,2.06)	62.4% (0.046)
Age<2 years included	6	2.31(1.61,3.32)	69.7% (0.006)
Controlling for potential confounders			
Unadjusted estimates	5	2.01(1.43,2.83)	53.4% (0.072)
Controlled for gestational age	5	2.29(1.50, 3.49)	74.3% (0.004)

NA: not available

**Figure captions**

Figure 1. Flow chart for study selection

Figure 2. Analysis of BPD and CP.

Figure 3. The Egger's test for publication bias test.

Figure 4. The Begg's test for publication bias test.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart for study selection

190x113mm (300 x 300 DPI)

Review only




Figure 2. Analysis of BPD and CP.

190x172mm (300 x 300 DPI)




Figure 3. The Egger's test for publication bias test.

190x126mm (300 x 300 DPI)

view only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. The Begg's test for publication bias test.

190x126mm (300 x 300 DPI)

view only



## The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis

### Supplement 1. Retrieval strategy of PubMed, EMBASE and Web of Science

Before 1 September 2017.

#### PubMed 195

Search (((((((Cerebral pals\*[Title/Abstract]) OR CP[Title/Abstract]) OR spastic\*[Title/Abstract]) OR Cerebral Palsy[Title/Abstract])) OR "Cerebral Palsy"[Mesh])) AND (((((((Dysplasia, Bronchopulmonary[Title/Abstract]) OR Bronchopulmonary Dysplasia[Title/Abstract]) OR BPD[Title/Abstract]) OR bronchopulmonary dysplasia[Title/Abstract])) OR "Bronchopulmonary Dysplasia"[Mesh])

#### EMBASE 523

Before 1 September 2017.

1 Cerebral palsy/

2 Cerebral pals\$.tw.

3 Little\$ disease.tw.

4 CP.tw.

5 (unilateral adj3 spastic\$.tw.

6 (hemiplegi\$ adj3 spastic\$.tw.

7 (diplegi\$ adj3 spastic\$.tw.

8 (tetrapleg\$ adj3 spastic\$.tw.

9 (triplegi\$ adj3 spastic\$.tw.

1  
2  
3  
4  
5 10 ((bilateral or bi-lateral) adj3 spastic\$.tw.

6  
7 11 (quadripleg\$ adj3 spastic\$.tw.

8  
9 12 or/1-11

10  
11 13 Bronchopulmonary Dysplasia.mp. or exp lung dysplasia/

12  
13 14 BPD.tw.

14  
15 15 Dysplasia, Bronchopulmonary.tw.

16  
17 16 Bronchopulmonary Dysplasia.tw.

18  
19 17 13 or 14 or 15 or 16

20  
21 18 12 and 17

22  
23 **Web of science 515**

24  
25 Before 1 September 2017.

26  
27 TS=(cerebral pals\* or spastic\* or quadripleg\* or cerebral palsy or CP)

28  
29 TS=(Bronchopulmonary Dysplasia or lung dysplasia or bronchopulmonary dysplasia or BPD or Dysplasia, Bronchopulmonary)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Supplement 2. Newcastle - Ottawa Quality Assessment Scale results for case-control studies**

Question	Option	Kim	Schlapbach	Tran
Is the case definition adequate?	a) yes, with independent validation * b) yes, eg record linkage or based on self reports c) no description	a	a	a
Representativeness of the cases	a) consecutive or obviously representative series of cases * b) potential for selection biases or not stated	a	b	b
Selection of Controls	a) community controls * b) hospital controls c) no description	b	b	b
Definition of Controls	a) no history of disease (endpoint)* b) no description of source	a	a	b
Comparability of cases and controls on the basis of the design or analysis	a) study controls for (Select the most important factor.* b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) *	a	a	a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

<p>Ascertainment of exposure</p>	<p>a) secure record (eg surgical records)*  b) structured interview where blind to case/control status*  c) interview not blinded to case/control status  d) written self report or medical record only  e) no description</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Same method of ascertainment for cases and controls</p>	<p>a) yes*  b) no</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Non-Response rate</p>	<p>a) same rate for both groups*  b) non-respondents described  c) rate different and no designation</p>	<p>b</p>	<p>a</p>	<p>b</p>

1  
2  
3  
4  
5 **Supplement 3. Newcastle - Ottawa Quality Assessment Scale results for cohort studies**  
6  
7  
8  
9  
10  
11  
12

Question	Option	Gagliardi	Lodha	Palta	Natarajan	Synnes	Van Marter	Wang	Bahir
Representativeness of the exposed cohort	a) truly representative of the average (describe) in the community * b) somewhat representative of the average in the community* c) selected group of users eg nurses, volunteered) no description of the derivation of the cohort	b	b	b	b	b	b	b	b
Selection of the Non-exposed cohort	a) drawn from the same community as the exposed cohort* b) drawn from a different source c) no description of the derivation of the non-exposed cohort	a	a	a	a	a	a	a	a
Ascertainment of exposure	a) secure record (eg surgical records)* b) structured interview* c) written self report d) no description	a	a	a	a	b	a	a	a
Demonstration that outcome of interest was not present at start of study	a) yes* b) no	a	a	a	a	a	a	a	a
Comparability of cohorts on the basis of the design or analysis	a) study controls for (select the most important factor)* b) study controls for any additional factor*	a	a	a	a	a	a	a	a

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Assessment of outcome	a) independent blind assessment* b) record linkage* c) self report d) no description	b	b	b	b	b	b	b	b
Was follow-up long enough for outcomes to occur	a) yes* b) no	b	b	b	a	a	a	a	a
Adequacy of follow up of cohort	a) complete follow up - all subjects accounted for* b) subjects lost to follow up unlikely to introduce bias - small number lost - > % (select an adequate %) follow up, or description provided of those lost) c) follow up rate < % (select an adequate %) and no description of those lost d) no statement	d	d	d	d	d	d	d	d

#### Supplement 4. Egger's and Begg's test for publication bias test

##### Begg's Test

adj. Kendall's Score (P-Q) = 6

Std. Dev. of Score = 9.59

Number of Studies = 9

$z = 0.63$

$\text{Pr} > |z| = 0.532$

$z = 0.52$  (continuity corrected)

$\text{Pr} > |z| = 0.602$  (continuity corrected)

##### Egger's test

	Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
slope	.1683662	.139195	1.21	0.266	-.1607777	.49751	
bias	-.8435039	.608102	-1.39	0.208	-2.281437	.5944288	



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a meta-analysis.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3 , 4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6





# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7,8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7,8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7,8
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9,10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9,10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	No

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020735.R2
Article Type:	Research
Date Submitted by the Author:	12-Jun-2018
Complete List of Authors:	Gou, Xiaoyun; West China Second University Hospital, Sichuan University, Chengdu 610041, China Yang, Lei; West China Second University Hospital, Sichuan University, Chengdu 610041, China Pan, Lingli; West China Second University Hospital, Sichuan University, Chengdu 610041, China Xiao, Dongqiong; West China Second University Hospital, Sichuan University, Chengdu 610041, China
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Neurology
Keywords:	bronchopulmonary dysplasia, cerebral palsy, neurodevelopment, infant

SCHOLARONE™  
Manuscripts

View Only

1  
2  
3 **1 The association between bronchopulmonary dysplasia and cerebral**  
4 **2 palsy in children: A meta-analysis**

5  
6  
7  
8 3 Xiaoyun Gou<sup>1,2#</sup>, Lei Yang<sup>1,2#</sup>, Lingli Pan<sup>1,2</sup>, Dongqiong Xiao<sup>1,2\*</sup>  
9

10 4 <sup>1</sup>Department of Pediatrics, West China Second University Hospital, Sichuan University,  
11  
12 5 Chengdu 610041, China  
13

14 6 <sup>2</sup>Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan  
15  
16 7 University), Ministry of Education, Chengdu 610041, China  
17  
18

19 8 # These authors contributed equally to the study.  
20

21 9 **\*Corresponding author**  
22

23  
24 10 **Dongqiong Xiao, MD**  
25

26 11 Department of Pediatrics,  
27

28  
29 12 West China Second University Hospital,  
30

31 13 Sichuan University, Chengdu, Sichuan 610041, China  
32  
33

34 14 Email: m13881749494@163.com  
35

36 15 Telephone: +86-28-85502273  
37  
38  
39 16  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

## 2 **Abstract**

3 **Objective:** To investigate the association between bronchopulmonary dysplasia  
4 (BPD) and the risk of cerebral palsy (CP) in children.

5 **Data sources** We used EMBASE, PubMed and Web of Science to conduct a  
6 meta-analysis of studies published before September 1 2017, written in English which  
7 titles or abstracts discussed an association between BPD and CP.

8 **Study selection:** Observational studies eg case control and cohort studies were  
9 included.

10 **Data extraction and synthesis:** All review stages were conducted by 2  
11 reviewers independently. Data synthesis was undertaken via meta-analysis of  
12 available evidence.

13 **Main outcomes and measures:** The prevalence of developing CP was measured  
14 after exposure to BPD.

15 **Results** Among 1234 initially identified studies, we selected those that addressed  
16 an association between BPD and CP according to our preselected inclusion criteria.  
17 Our meta-analysis included 11 studies. According to a random effect model, BPD was  
18 significantly associated with cerebral palsy (ORs, 2.10; 95% CI, 1.57, 2.82) in  
19 preterm infants. Factors explaining differences in the study results included study  
20 design, the definition of BPD, the time of diagnosis of CP, and whether the studies  
21 adjusted for potential confounders.

22 **Conclusion** This study suggests that BPD is a risk factor for cerebral palsy.  
23 Further studies are required to confirm these results and to detect the influence of  
24 variables across studies.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Keywords:** bronchopulmonary dysplasia; cerebral palsy; neurodevelopment; infant

2

For peer review only

1  
2  
3 **1 Strengths and limitations of the study**  
4

5  
6 2 \*No consensus exists regarding the association between BPD and CP in children.  
7

8 3 \*The clear and univocal definition of BPD may explain the differences of the results  
9  
10 4 of studies which evaluated the association between BPD and CP in children.  
11

12  
13 5 \*The number of studies included is limited, and therefore, the results of the  
14  
15 6 meta-analysis should be interpreted with caution.  
16

17 7 \*Observational study designs rarely can establish causality.  
18  
19

20 8  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Introduction

2 Despite advances in obstetric and neonatal care, the prevalence of developing  
3 cerebral palsy (CP) was approximately at 0.2% during the past decades<sup>1</sup>, and the  
4 etiology of CP remains poorly understood. Evidence shows that prenatal factors,  
5 including maternal age <sup>2</sup>, education <sup>3 4</sup>, obesity <sup>5-7</sup>, race <sup>8</sup>, chorioamnionitis<sup>1</sup> and  
6 hypertension <sup>9</sup> contribute to CP.

7 Bronchopulmonary dysplasia (BPD) has been implicated as a potential neonatal  
8 factor of CP<sup>10</sup>. BPD is common in preterm and low birthweight infants born at 24 to  
9 26 weeks of gestation<sup>11</sup>. The lung is in the canalicular stage from 16 to 28 weeks, and  
10 it is in the saccular stage from 28 to 36 weeks. Alveoli are not uniformly present until  
11 36 weeks. Thus, premature birth and the initiation of pulmonary gas exchange arrest  
12 normal alveolar and distal vascular development, and subsequent BPD<sup>11</sup>. Maternal  
13 infection, especially maternal chorioamnionitis was associated with an increased risk  
14 of BPD<sup>12</sup>. The inconsistencies in the definition of BPD contribute to variation in  
15 incidence of BPD. BPD is a chronic lung disease developed after mechanical  
16 ventilation or oxygen inhalation usually occurring in certain premature neonates with  
17 respiratory distress syndrome. Some studies defined as oxygen dependency at 36  
18 weeks post-menstrual age (PMA), yet, others defined as 28 or more days duration of  
19 oxygen dependency during hospitalization <sup>12</sup>. Cerebral palsy, cognitive delay, and  
20 hearing loss are important and commonly reported adverse outcomes in very  
21 premature infants<sup>13</sup>. It is postulated that BPD can lead to neonatal brain injury and  
22 subsequent CP<sup>14</sup>.

23 A number of studies have assessed the relationship between BPD and CP in  
24 premature infants, the association between BPD and CP was inconsistent. Some of the  
25 studies have not examined a significant association<sup>15 16</sup>. For example, one study  
26 defined BPD as 28 days duration of oxygen dependency<sup>15</sup> and reported insignificant

1 association between BPD and CP, additionally, another study<sup>14</sup> evaluated the  
2 association between BPD (oxygen dependency at 36 weeks) and quadriparesis and  
3 diparesis, and reported the same result. However, any other studies<sup>17 18</sup> showed a  
4 significant association between BPD and CP. We conducted a meta-analysis to  
5 evaluate the potential association between BPD and CP in preterm infants.

For peer review only



1  
2  
3 1  
4  
56 **2 Methods**  
7

8 **3 Retrieval of studies.** The PubMed, EMBASE, and Web of Science databases were  
9  
10 4 searched through September 1, 2017. The search of bronchopulmonary dysplasia was  
11  
12 5 performed using the following keywords and subject terms: “bronchopulmonary  
13  
14 6 dysplasia”, or “BPD\*”, or “lung dysplasia”, or “Dysplasia, Bronchopulmonary”, or  
15  
16 7 “Bronchopulmonary Dysplasia”, using “OR” to link relevant text within the search  
17  
18 8 field. To acquire studies related to cerebral palsy, “OR” was used to associate the key  
19  
20 9 words, which included “cerebral palsy”, “Crebral pals\*”, “spastic\*”, “quadripleg\*”  
21  
22 10 and “CP”. We combined these terms using “AND” to retrieve the studies (Supplement  
23  
24 11 1). We restricted the search to human studies published in English. The retrieved  
25  
26 12 studies were screened by reading the titles and abstracts, and two authors (Xiaoyun  
27  
28 13 Gou and Lei Yang) subsequently read the full text of the remaining publications  
29  
30 14 independently and then discussed disagreements to reach a consensus.

31  
32 15 **Patient and Public Involvement.** Not required, a meta-analysis  
33

34 16 **Study selection.** The study inclusion criteria were as follows: (1) the study evaluated  
35  
36 17 the association between bronchopulmonary dysplasia (BPD) and the risk of CP in  
37  
38 18 children; (2) the study was published in English; (3) case-control or cohort study  
39  
40 19 design; (4) the study described the assessment of exposure and outcome, the relevant  
41  
42 20 exposure included any type of BPD. Relevant outcome included any definition of CP.  
43  
44 21 The association between exposure and outcome was reported by unadjusted and/or  
45  
46 22 adjusted relative ratios (RRs) and corresponding 95% confidence intervals (CIs),  
47  
48 23 unadjusted and/or adjusted odds ratios (ORs) estimates and 95% CIs or reported that  
49  
50 24 could have allowed RRs/ORs to be calculated (e.g. number of cases of BPD events  
51  
52 25 and total number of children with CP).  
53  
54  
55  
56  
57  
58  
59  
60

1           The exclusion criteria were as follows: (1) a review or meta-analysis or a case  
2 report; (2) the study was not published in English; (3) the article described an animal  
3 experiment study; (4) a study with overlapping data; (5) the articles with unusable  
4 data that was reported with that (e.g. neurological lesion before discharge or cerebral  
5 palsy between BPD and without BPD, we cannot know the exactly result of the  
6 association between cerebral palsy and BPD; neurodevelopmental outcomes  
7 (Neuropsychological Performance, neurodevelopmental disability) including cerebral  
8 palsy but not only cerebral palsy) was excluded.

9   **Data extraction.** The data were independently extracted from the studies by two  
10 reviewers (Xiaoyun Gou and Lei Yang) and included the name of the first author,  
11 publication year, the country of the participants, study design, sample size, gestational  
12 age and/or birthweight, following years, BPD definition, primary outcome (the  
13 association between BPD and risk of CP), and adjusted confounders.

14   **Quality evaluation.** The two reviewers (Xiaoyun Gou and Lei Yang) independently  
15 used the Newcastle-Ottawa Scale (NOS)<sup>19</sup> to examine all included studies for their  
16 methodological quality. The reviewers evaluated the quality score via examine the  
17 selection of the study population, comparability and evaluation of exposure and  
18 outcome, with a maximum score of nine. The reviewers resolved disagreements in the  
19 manner previously described.

20   **Statistical analysis.** The original studies included used ORs and/or RRs and 95% CIs to  
21 assess the association between BPD and the risk of CP in children. The ORs and RRs  
22 were directly considered as ORs when the outcome is rare<sup>1</sup>. We pooled ORs and/or  
23 RRs of each study separately using the Der Simonian-Laird formula (random-effects  
24 model)<sup>20</sup>. Statistical heterogeneity<sup>21</sup> between the studies was assessed using the Q  
25 and  $I^2$  statistics. Values of  $I^2 > 50\%$  and  $P < 0.1$  indicated high heterogeneity<sup>1</sup>. We  
26 conducted a stratified analysis based on study design (case-control, cohort), BPD type

1 (oxygen dependency at 36 weeks' post-menstrual age (PMA), 28 days duration of  
2 oxygen dependency during hospitalization, severe BPD including mechanical  
3 ventilation at 36 weeks, not defined BPD), diagnostic criteria for CP (Age <2 years,  
4 other), confounding variables (gestational age, unadjusted estimated).

5 We used Egger's <sup>22</sup> and Begg's <sup>23</sup> tests to assess the publication bias, which was  
6 considered to be statistically significant when  $p < 0.05$ . We used Stata software,  
7 version 12.0 (Stata Corp, College Station, TX) to perform the statistical tests. We  
8 performed a "Test of Subgroup differences" in software such as Review Manager 5.3  
9 (Cochrane).

1  
2  
3 1  
4  
56 **2 Results**

8 **3 Literature search.** We identified 1234 potential studies: 195 from PubMed, 523 from  
9  
10 4 EMBASE, 515 from Web of Science and 1 additional study from the related reference.  
11  
12 5 After careful screening, 11 studies that reported the association between BPD and the  
13  
14 6 risk of CP in children were selected for inclusion in this study (see Figure 1). These  
15  
16 7 11 included studies are summarized in Table 1.

18 **8 Characteristics and quality of the included studies.** The included studies were  
19  
20 9 published between 1999 and 2017. Eleven studies evaluated the association between  
21  
22 10 BPD and cerebral palsy in preterm infants. Two<sup>15 16</sup> of these studies reported no  
23  
24 11 significant association. Eight of the included studies were cohort studies and three<sup>15 17</sup>  
25  
26 12 <sup>18</sup> of the studies were case-control studies of a high quality (NOS>5, Supplement 2,  
27  
28 13 Supplement 3). All the studies evaluated the association between BPD and CP in  
29  
30 14 preterm neonates with ORs.

32 **15 Bronchopulmonary dysplasia (BPD) and cerebral palsy (CP).** When the study  
33  
34 16 results were analyzed using random effects model, BPD was significantly associated  
35  
36 17 with CP (Figure 2). These infants were preterm infants.

38  
39 **18 Stratified analysis.** A stratified analysis was conducted to determine whether there  
40  
41 19 are any significantly different results across the subgroups considered (Table 2). The  
42  
43 20 case-control studies did not produce significant summary ORs (1.27; 95%CI, 0.98,  
44  
45 21 1.64,  $I^2=72\%$ ), yet, a significant association was seen in cohort studies ORs (2.09;  
46  
47 22 95%CI, 1.86, 2.34,  $I^2=83\%$ ). And the subgroup difference was significant when  
48  
49 23 stratified by study design (ORs, 1.27; 95%CI, 0.98, 1.64; vs ORs, 2.09; 95%CI, 1.86,  
50  
51 24 2.34;  $p<0.05$ , Table 2).

1 Six studies<sup>14 16 18 24-26</sup> evaluated the association between BPD (oxygen  
2 dependence at 36 weeks) and CP in premature infants, with only 1 reporting<sup>16</sup> a no  
3 significant association (Figure 2). One study<sup>15</sup> evaluated the association between BPD  
4 (oxygen dependence at 28 days) and CP in premature infants with no significant  
5 association (OR 1.12, 95%CI, 0.84, 1.49). Three studies<sup>17 27 28</sup> evaluated the  
6 association (OR 2.80, 95%CI, 2.08, 3.79,  $I^2=30.5%$ ) without mentioned BPD  
7 definition, and 2 studies<sup>14 29</sup> show severe BPD or mechanical ventilation at 36 weeks  
8 (OR 3.44, 95%CI, 1.56, 7.60,  $I^2=63.7%$ ). And the subgroup difference was significant  
9 when stratified by BPD definition ( $p<0.00001$ , Table 2)

10 The definition of CP differed greatly among studies of preterm infants (Table 2).  
11 Of the four studies<sup>14 16 24 28</sup> that provided adequate information, four studies provided  
12 a minimum age of 2 years for diagnosing CP; Some studies confirm the diagnosis by  
13 performing examination, while others did not. Some studies excluded children with  
14 congenital anomalies<sup>15 16 28</sup>, while others<sup>14 24</sup> did not specify any exclusion criteria.

15 Five studies of BPD(PMA) in premature infants reported ORs controlled for  
16 gestational age. Association between BPD and CP remains significant both adjusted  
17 or unadjusted by gestational age (ORs, 2.64; 95%CI, 2.27, 3.08; vs ORs, 1.48; 95%CI,  
18 1.28, 1.70;  $p<0.00001$ , Table 2).

19 **Publication bias.** Asymmetry and publication bias were evaluated by Egger's and  
20 Begg's tests (Figure 3, Figure 4). The pooled results did not support the presence of  
21 significant publication bias (all  $p>0.05$ , Supplement 4).

22

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2 Discussion

3 To our knowledge, this article is the first meta-analysis of the relationship  
4 between BPD and risk of CP in children. The results of this meta-analysis, which  
5 included 11 studies, showed evidence that BPD appears to be associated with CP in  
6 preterm infants.

7 BPD might affect the neurodevelopment outcome of infants through multiple  
8 pathways. A growing body evidence supports that BPD contributes to neonatal brain  
9 injury<sup>30</sup>. Experimental BPD with hypoxia leads to central nervous system damage,  
10 and subsequent CP<sup>31 32</sup>. Indeed, the preterm infants with BPD accompany with  
11 hypoxia often had oligodendrocytes maturation arrest or injury<sup>33-35</sup>, disruption of  
12 myelination and demyelination, and then cause white matter injury<sup>35</sup> and impaired  
13 neurodevelopmental outcomes<sup>32</sup>.

14 To better understand the relationship between BPD and CP, it is crucial to  
15 develop consensus definitions of BPD. Most published reports do not apply specific  
16 diagnostic criteria for BPD, as a group, these studies produced heterogeneous results.  
17 The results of the stratified analysis suggest that a stronger association is seen when  
18 used severe or mechanical ventilation at 36 weeks diagnostic criteria in the studies.  
19 The studies do not include strict criteria may lead to an over-diagnosis of BPD, which  
20 may contribute to the evidence of heterogeneity.

21 The definition of CP varied between studies; although CP can be difficult to  
22 diagnosis in children younger than 2 years, 1 study made the diagnosis in infants  
23 younger than 12 months. A consensus definition of CP is required.

24 Some studies report significant associations between BPD and CP after adjust for  
25 potential confounders<sup>15 16 18 25 26 28</sup>. Although gestational age appears to be a possible

1 confounder, it may not lie directly in the causal pathway between BPD and CP.  
2 Gestational age can be considered as a confounder, as a premature baby is born at any  
3 gestational age and a lot of time later may develop BPD. The study would falsely  
4 diminish the association between BPD and CP without considering gestational age as  
5 a confounder. BPD is associated with premature delivery, and low gestational age,  
6 which is associated with a host of intrinsic vulnerabilities within the brain, that have  
7 been implicated in the pathogenesis of CP. Therefore, if low gestational age resulting  
8 in BPD plays a direct role in the pathogenesis of CP, then adjusting for gestational age  
9 will falsely diminish the observed association between BPD and CP. One study<sup>16</sup> of  
10 BPD in premature infants found no association when controlling for the confounder  
11 variables including gestational age. It is unclear if this is because BPD does not  
12 contribute independently to CP, or perhaps because gestational age lies on the causal  
13 pathway.

14 Other factors may interact with BPD in the pathogenetic pathway leading to CP.  
15 For example, child sex, IVH, Apgar score at 5 minutes, small for gestational age  
16 (SGA), which may contribute to CP lies on the causal pathway. Accordino et al.<sup>36</sup>  
17 demonstrated that premature spontaneous birth and iatrogenic preterm birth are  
18 significantly associated with CP. The reasons of the difference contribute to  
19 neurological damage would be related to infection. Although the studies controlled for  
20 some confounder variables, many other factors that contribute to CP may not be  
21 excluded.

22 Our meta-analysis is subject to limitations as follows. Firstly, we only included  
23 articles published in English. Secondly, there may be publication bias, incomplete  
24 ascertainment of published studies, and errors in data abstraction. Thirdly, the number  
25 of studies included is small, and therefore, the results of this meta-analysis should be

1  
2  
3 1 interpreted with caution. Furthermore, the bias inherent to observational studies are  
4  
5 2 not eliminated in a quantitative synthesis.  
6

7  
8 3 Our meta-analysis has some merits. First, the study evaluated the association  
9  
10 4 between BPD and CP. Second, the study used stratified analysis to explore the  
11  
12 5 heterogeneity source, and the different definition of BPD may contribute to the source  
13  
14 6 of heterogeneity.  
15

16 7 In conclusion, our pooled analyses provide evidence that BPD is significantly  
17  
18 8 associated with cerebral palsy in children. Future studies that consider additional  
19  
20 9 factors are required to resolve this issue.  
21

22  
23 10  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **1 Author contributions**

4  
5  
6 2 XG and LY contributed to the conception and design of the study, as well as to the  
7  
8 3 drafting of this article. LP contributed to the collection and analysis of the data. DX  
9  
10 4 contributed to the conception and design of the study and approved the final version  
11  
12 5 of the manuscript for submission for publication.

13  
14 **6 Funding**

15  
16  
17 7 No financial support for this work

18  
19 **8 Ethical approval**

20  
21  
22 9 Not available, a meta-analysis

23  
24 **10 Patients and Public Involvement statement**

25  
26  
27 11 Patients and or Public were not involved

28  
29 **12 Competing financial interests**

30  
31  
32 13 The authors declare that they have no competing financial interests.

33  
34 **14 Data sharing statement**

35  
36  
37 15 No additional data are available.

## References

1. Wu YW, Colford JM, Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. *Jama* 2000;284(11):1417-24. [published Online First: 2000/09/16]
2. Pan C, Deroche CB, Mann JR, et al. Is prepregnancy obesity associated with risk of cerebral palsy and epilepsy in children? *J Child Neurol* 2014;29(12):Np196-201. doi: 10.1177/0883073813510971 [published Online First: 2013/12/18]
3. Villamor E, Tedroff K, Peterson M, et al. Association Between Maternal Body Mass Index in Early Pregnancy and Incidence of Cerebral Palsy. *Jama* 2017;317(9):925-36. doi: 10.1001/jama.2017.0945 [published Online First: 2017/03/08]
4. Persson M, Johansson S, Villamor E, et al. Maternal overweight and obesity and risks of severe birth-asphyxia-related complications in term infants: a population-based cohort study in Sweden. *PLoS Med* 2014;11(5):e1001648. doi: 10.1371/journal.pmed.1001648 [published Online First: 2014/05/23]
5. Wang Y, Tang S, Xu S, et al. Maternal Body Mass Index and Risk of Autism Spectrum Disorders in Offspring: A Meta-analysis. *Sci Rep* 2016;6:34248. doi: 10.1038/srep34248 [published Online First: 2016/10/01]
6. Crisham Janik MD, Newman TB, Cheng YW, et al. Maternal diagnosis of obesity and risk of cerebral palsy in the child. *J Pediatr* 2013;163(5):1307-12. doi: 10.1016/j.jpeds.2013.06.062 [published Online First: 2013/08/13]

- 1  
2  
3  
4 7. Forthun I, Wilcox AJ, Strandberg-Larsen K, et al. Maternal Prepregnancy BMI and Risk of  
5  
6 Cerebral Palsy in Offspring. *Pediatrics* 2016;138(4) doi: 10.1542/peds.2016-0874  
7  
8 [published Online First: 2016/09/10]  
9  
10  
11 8. Bear JJ, Wu YW. Maternal Infections During Pregnancy and Cerebral Palsy in the Child.  
12  
13 *Pediatr Neurol* 2016;57:74-9. doi: 10.1016/j.pediatrneurol.2015.12.018 [published  
14  
15 Online First: 2016/02/10]  
16  
17  
18 9. Kronenberg ME, Raz S, Sander CJ. Neurodevelopmental outcome in children born to  
19  
20 mothers with hypertension in pregnancy: the significance of suboptimal intrauterine  
21  
22 growth. *Developmental Medicine and Child Neurology* 2006;48(3):200-06. doi:  
23  
24 10.1017/s0012162206000430  
25  
26  
27  
28 10. Bregman J, Farrell EE. NEURODEVELOPMENTAL OUTCOME IN INFANTS WITH  
29  
30 BRONCHOPULMONARY DYSPLASIA. *Clinics in Perinatology* 1992;19(3):673-94.  
31  
32  
33 11. Coalson JJ. Pathology of new bronchopulmonary dysplasia. *Seminars in neonatology : SN*  
34  
35 2003;8(1):73-81. doi: 10.1016/s1084-2756(02)00193-8  
36  
37  
38 12. Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in  
39  
40 pathogenesis, epidemiology and definition. *Seminars in neonatology : SN*  
41  
42 2003;8(1):63-71. doi: 10.1016/s1084-2756(02)00192-6  
43  
44  
45 13. Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia, brain  
46  
47 injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at  
48  
49 18 months - Results from the trial of indomethacin prophylaxis in preterms.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Jama-Journal of the American Medical Association* 2003;289(9):1124-29. doi:

10.1001/jama.289.9.1124

14. Van Marter LJ, Kuban KCK, Allred E, et al. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?

*Archives of Disease in Childhood-Fetal and Neonatal Edition* 2011;96(1):F20-F29. doi:

10.1136/adc.2010.183012

15. Kim JN, Namgung R, Chang W, et al. Prospective evaluation of perinatal risk factors for cerebral palsy and delayed development in high risk infants. *Yonsei Medical Journal*

1999;40(4):363-70.

16. Bashir RA, Bhandari V, Vayalthrikkovil S, et al. Chorioamnionitis at birth does not increase the risk of neurodevelopmental disability in premature infants with bronchopulmonary

dysplasia. *Acta Paediatr* 2016;105(11):e506-e12. doi: 10.1111/apa.13556 [published

Online First: 2016/08/24]

17. Tran U, Gray PH, O'Callaghan MJ. Neonatal antecedents for cerebral palsy in extremely preterm babies and interaction with maternal factors. *Early Human Development*

2005;81(6):555-61. doi: 10.1016/j.earhumdev.2004.12.009

18. Schlapbach LJ, Ersch J, Adams M, et al. Impact of chorioamnionitis and preeclampsia on neurodevelopmental outcome in preterm infants below 32 weeks gestational age. *Acta*

*Paediatrica* 2010;99(10):1504-09. doi: 10.1111/j.1651-2227.2010.01861.x

- 1  
2  
3  
4 19. Zhu T, Tang J, Zhao F, et al. Association between maternal obesity and offspring Apgar  
5  
6 score or cord pH: a systematic review and meta-analysis. *Sci Rep* 2015;5:18386. doi:  
7  
8 10.1038/srep18386 [published Online First: 2015/12/23]  
9  
10  
11 20. Hartzel J, Agresti A, Caffo B. Multinomial logit random effects models. *Statistical Modelling*  
12  
13 2001;1(2):81-102. doi: 10.1177/1471082x0100100201  
14  
15  
16 21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.  
17  
18 *Bmj* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online First:  
19  
20 2003/09/06]  
21  
22  
23  
24 22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,  
25  
26 graphical test. *Bmj* 1997;315(7109):629-34. [published Online First: 1997/10/06]  
27  
28  
29 23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication  
30  
31 bias. *Biometrics* 1994;50(4):1088-101. [published Online First: 1994/12/01]  
32  
33  
34 24. Synnes A, Luu TM, Moddemann D, et al. Determinants of developmental outcomes in a  
35  
36 very preterm Canadian cohort. *Archives of Disease in Childhood-Fetal and Neonatal*  
37  
38 *Edition* 2017;102(3):F235-F43. doi: 10.1136/archdischild-2016-311228  
39  
40  
41  
42 25. Natarajan G, Pappas A, Shankaran S, et al. Outcomes of extremely low birth weight  
43  
44 infants with bronchopulmonary dysplasia: Impact of the physiologic definition. *Early*  
45  
46 *Human Development* 2012;88(7):509-15. doi: 10.1016/j.earlhumdev.2011.12.013  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 26. Gagliardi L, Bellu R, Zanini R, et al. Bronchopulmonary dysplasia and brain white matter  
5  
6 damage in the preterm infant: A complex relationship. *Paediatric and Perinatal*  
7  
8 *Epidemiology* 2009;23(6):582-90.  
9  
10  
11 27. Lodha A, Sauve R, Tand S, et al. Does advanced maternal age affect long term neuro  
12  
13 developmental outcomes in preterm infants at 3 years of age? *Paediatrics and Child*  
14  
15 *Health* 2011;16:33A.  
16  
17  
18 28. Wang L-W, Lin Y-C, Wang S-T, et al. Hypoxic/Ischemic and Infectious Events Have  
19  
20 Cumulative Effects on the Risk of Cerebral Palsy in Very-Low-Birth-Weight Preterm  
21  
22 Infants. *Neonatology* 2014;106(3):209-15. doi: 10.1159/000362782  
23  
24  
25  
26 29. Palta M, Sadeh-Badawi M, Evans M, et al. Functional assessment of a multicenter very  
27  
28 low-birth-weight cohort at age 5 years. *Archives of Pediatrics & Adolescent Medicine*  
29  
30 2000;154(1):23-30.  
31  
32  
33  
34 30. Gallini F, Arena R, Stella G, et al. Neurodevelopmental outcomes of premature infants with  
35  
36 bronchopulmonary dysplasia. *Acta bio-medica : Atenei Parmensis* 2014;85(1):30-4.  
37  
38  
39 31. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids  
40  
41 on mortality and cerebral palsy in preterm infants: Effect modification by risk for  
42  
43 chronic lung disease. *Pediatrics* 2005;115(3):655-61. doi: 10.1542/peds.2004-1238  
44  
45  
46  
47 32. Shankaran S, Johnson Y, Langer JC, et al. Outcome of extremely-low-birth-weight infants  
48  
49 at highest risk: Gestational age <= 24 weeks, birth weight <= 750 g, and 1-minute  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4                   Apgar <= 3. *American Journal of Obstetrics and Gynecology* 2004;191(4):1084-91.

5  
6                   doi: 10.1016/j.ajog.2004.05.032

7  
8                   33. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors  
9  
10                   to hypoxia-ischemia. *J Neurosci* 2002;22(2):455-63.

11  
12  
13                   34. Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal white  
14                   matter in premature birth. *Stroke* 2007;38(2 Suppl):724-30. doi:

15  
16                   10.1161/01.STR.0000254729.27386.05

17  
18                   35. Back SA, Rosenberg PA. Pathophysiology of glia in perinatal white matter injury. *Glia*  
19                   2014;62(11):1790-815. doi: 10.1002/glia.22658 [published Online First: 2014/03/31]

20  
21                   36. Accordino F, Consonni S, Fedeli T, et al. Risk factors for cerebral palsy in PPRM and  
22                   preterm delivery with intact membranes. *Journal of Maternal-Fetal & Neonatal*  
23                   *Medicine* 2016;29(23):3854-59. doi: 10.3109/14767058.2016.1149562

**Table 1. Characteristics of the included studies.**

Study	Publication year	country	Study design	Gestational age/ birth weight	Sample size	BPD definition	Primary outcome	adjusted confounder variables	NOS score
Gagliardi <sup>26</sup>	2009	Italy	Cohort study	<32 weeks and BW<1500g	1209	BPD (at 36 weeks PMA)	ORs=2.16(CI, 1.1-3.9)	GA, propensity score for prolonged ventilation, centre	6
Kim <sup>15</sup>	1999	Korea	Case-control	<37 weeks	184	BPD (oxygen dependence at 28 days)	ORs=1.12(CI, 0.85-1.5)	Apgar score at 5 min, IVH, PDA, sepsis, duration of mechanical ventilation	7
Lodha <sup>27</sup>	2011	Canada	Cohort study	<28 weeks	918	NA	ORs=2(CI, 1.2-3.2)	NA	6
Natarajan <sup>25</sup>	2012	NA	Cohort study	<27 weeks BW<1000g	1189	BPD (at 36 weeks PMA)	ORs=2.41(CI, 1.4-4.13)	GA, male gender, SGA, maternal education, surgical NEC, IVH or PVL	7
Palta <sup>29</sup>	2000	USA	Cohort study	BW<1500g	1024	Severe BPD	ORs=2.3(CI, 1.2-4.6)	NA	6
Schlapbach <sup>18</sup>	2010	Switzerland	Case-control study	<32 weeks	99	BPD (at 36 weeks PMA)	ORs=3.75(CI, 1.08-11.14)	gestational age, birth weight, postnatal growth, mechanical ventilation	7
Synnes <sup>24</sup>	2017	Canada	Cohort study	<29 weeks	3700	BPD (at 36 weeks PMA)	ORs=1.42(CI, 1.17-1.73)	NA	8
Tran <sup>17</sup>	2005	Australia	Case control	<27 weeks	150	NA home oxygen	ORs=3.4(CI, 1.2-9.4)	NA	6
Van Marter <sup>14</sup>	2011	USA	Cohort study	<28 weeks	1047	BPD (at 36 weeks PMA) BPD (Mechanical ventilation at	ORs=1.77(CI, 1.02-3.77) ORs=5.16(CI, 2.62-10.16)	NA	8



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

						36 weeks)			
Wang <sup>28</sup>	2014	China	Cohort study	GA<30 weeks and BW<1500g	5807	Not mentioned	ORs=3.14(CI, 2.61-3.85)	GA, BW, sex, ROP grade≥III, grade III/IV IVH and PVL	8
Bashir <sup>16</sup>	2016	Canada	Retrospective observational study	BW<1250g	1563	BPD (at 36 weeks PMA)	ORs=1.3(CI, 0.87-1.96)	GA, male gender, ANCS use, Apgar score<7 at 5 minutes, SGA, postnatal steroids, blood transfusion, PDA, IVH grade≥III and/ or PVL, ROP grade≥III and/ or required laser treatment and postnatal sepsis	8

For peer review only

**Table 2. Pooled results of the associations between bronchopulmonary dysplasia and cerebral palsy in children.**

Variables	Studies (n)	ORs(95%CI)	$I^2$ (p-value for heterogeneity)	$p$
Total	11	2.10(1.57,2.82)	82.5% (0.000)	
Study design				
Case-control	3	1.27 (0.98, 1.64)	72% (0.03)	$p=0.0006$
Cohort	8	2.09 (1.86, 2.34)	83% (<0.00001)	
Definition of BPD				
Oxygen dependence at 36 weeks	6	1.67(1.33,2.11)	33.2% (0.187)	$p<0.00001$
Oxygen dependence at 28 days	1	1.12(0.84,1.49)	NA	
Severe BPD (mechanical ventilation)	2	3.44(1.56,7.60)	63.7%(0.097)	
Not mentioned BPD type	3	2.80(2.08, 3.79)	30.5% (0.237)	
Diagnostic criteria for cerebral palsy				
Age $\geq$ 2 years only	6	2.62(2.26, 3.05)	71% (0.004)	$p<0.00001$
Age<2 years included	4	1.42(1.22, 1.64)	64% (0.04)	
Controlling for potential confounders				
Unadjusted estimates	6	1.48(1.28, 1.70)	64% (0.02)	$p<0.00001$
Controlled for gestational age	5	2.64(2.27, 3.08)	75% (0.003)	

NA: not available

**Figure captions**

Figure 1. Flow chart for study selection

Figure 2. Analysis of BPD and CP.

Figure 3. The Egger's test for publication bias test.

Figure 4. The Begg's test for publication bias test.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Flow chart for study selection

190x113mm (300 x 300 DPI)

Review only




Figure 2. Analysis of BPD and CP.

190x172mm (300 x 300 DPI)




Figure 3. The Egger's test for publication bias test.

190x126mm (300 x 300 DPI)

view only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4. The Begg's test for publication bias test.

190x126mm (300 x 300 DPI)

view only

## The association between bronchopulmonary dysplasia and cerebral palsy in children: A meta-analysis

### Supplement 1. Retrieval strategy of PubMed, EMBASE and Web of Science

Before 1 September 2017.

#### PubMed 195

Search (((((((Cerebral pals\*[Title/Abstract]) OR CP[Title/Abstract]) OR spastic\*[Title/Abstract]) OR Cerebral Palsy[Title/Abstract])) OR "Cerebral Palsy"[Mesh])) AND (((((((Dysplasia, Bronchopulmonary[Title/Abstract]) OR Bronchopulmonary Dysplasia[Title/Abstract]) OR BPD[Title/Abstract]) OR bronchopulmonary dysplasia[Title/Abstract])) OR "Bronchopulmonary Dysplasia"[Mesh])

#### EMBASE 523

Before 1 September 2017.

1 Cerebral palsy/

2 Cerebral pals\$.tw.

3 Little\$ disease.tw.

4 CP.tw.

5 (unilateral adj3 spastic\$.tw.

6 (hemiplegi\$ adj3 spastic\$.tw.

7 (diplegi\$ adj3 spastic\$.tw.

8 (tetrapleg\$ adj3 spastic\$.tw.

9 (triplegi\$ adj3 spastic\$.tw.



1  
2  
3  
4  
5 10 ((bilateral or bi-lateral) adj3 spastic\$.tw.

6  
7 11 (quadripleg\$ adj3 spastic\$.tw.

8  
9 12 or/1-11

10  
11 13 Bronchopulmonary Dysplasia.mp. or exp lung dysplasia/

12  
13 14 BPD.tw.

14  
15 15 Dysplasia, Bronchopulmonary.tw.

16  
17 16 Bronchopulmonary Dysplasia.tw.

18  
19 17 13 or 14 or 15 or 16

20  
21 18 12 and 17

22  
23 **Web of science 515**

24  
25 Before 1 September 2017.

26  
27 TS=(cerebral pals\* or spastic\* or quadripleg\* or cerebral palsy or CP)

28  
29 TS=(Bronchopulmonary Dysplasia or lung dysplasia or bronchopulmonary dysplasia or BPD or Dysplasia, Bronchopulmonary)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Supplement 2. Newcastle - Ottawa Quality Assessment Scale results for case-control studies**

Question	Option	Kim	Schlapbach	Tran
Is the case definition adequate?	a) yes, with independent validation * b) yes, eg record linkage or based on self reports c) no description	a	a	a
Representativeness of the cases	a) consecutive or obviously representative series of cases * b) potential for selection biases or not stated	a	b	b
Selection of Controls	a) community controls * b) hospital controls c) no description	b	b	b
Definition of Controls	a) no history of disease (endpoint)* b) no description of source	a	a	b
Comparability of cases and controls on the basis of the design or analysis	a) study controls for (Select the most important factor.* b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) *	a	a	a

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

<p>Ascertainment of exposure</p>	<p>a) secure record (eg surgical records)*  b) structured interview where blind to case/control status*  c) interview not blinded to case/control status  d) written self report or medical record only  e) no description</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Same method of ascertainment for cases and controls</p>	<p>a) yes*  b) no</p>	<p>a</p>	<p>a</p>	<p>a</p>
<p>Non-Response rate</p>	<p>a) same rate for both groups*  b) non-respondents described  c) rate different and no designation</p>	<p>b</p>	<p>a</p>	<p>b</p>

1  
2  
3  
4  
5 **Supplement 3. Newcastle - Ottawa Quality Assessment Scale results for cohort studies**  
6  
7  
8  
9  
10  
11  
12

Question	Option	Gagliardi	Lodha	Palta	Natarajan	Synnes	Van Marter	Wang	Bahir
Representativeness of the exposed cohort	a) truly representative of the average (describe) in the community * b) somewhat representative of the average in the community* c) selected group of users eg nurses, volunteered) no description of the derivation of the cohort	b	b	b	b	b	b	b	b
Selection of the Non-exposed cohort	a) drawn from the same community as the exposed cohort* b) drawn from a different source c) no description of the derivation of the non-exposed cohort	a	a	a	a	a	a	a	a
Ascertainment of exposure	a) secure record (eg surgical records)* b) structured interview* c) written self report d) no description	a	a	a	a	b	a	a	a
Demonstration that outcome of interest was not present at start of study	a) yes* b) no	a	a	a	a	a	a	a	a
Comparability of cohorts on the basis of the design or analysis	a) study controls for (select the most important factor)* b) study controls for any additional factor*	a	a	a	a	a	a	a	a

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Assessment of outcome	a) independent blind assessment* b) record linkage* c) self report d) no description	b	b	b	b	b	b	b	b
Was follow-up long enough for outcomes to occur	a) yes* b) no	b	b	b	a	a	a	a	a
Adequacy of follow up of cohort	a) complete follow up - all subjects accounted for* b) subjects lost to follow up unlikely to introduce bias - small number lost - > % (select an adequate %) follow up, or description provided of those lost) c) follow up rate < % (select an adequate %) and no description of those lost d) no statement	d	d	d	d	d	d	d	d

#### Supplement 4. Egger's and Begg's test for publication bias test

##### Begg's Test

adj. Kendall's Score (P-Q) = 6

Std. Dev. of Score = 9.59

Number of Studies = 9

$z = 0.63$

$\text{Pr} > |z| = 0.532$

$z = 0.52$  (continuity corrected)

$\text{Pr} > |z| = 0.602$  (continuity corrected)

##### Egger's test

	Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
slope	.1683662	.139195	1.21	0.266	-.1607777	.49751	
bias	-.8435039	.608102	-1.39	0.208	-2.281437	.5944288	



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a meta-analysis.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3 , 4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	6



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7,8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	7,8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	7,8
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9,10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9,10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	No

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>